id	sid	tid	token	lemma	pos
dpc-4183	1	1	dermatology	dermatology	NOUN
dpc-4183	1	2	:	:	PUNCT
dpc-4183	1	3	practical	practical	ADJ
dpc-4183	1	4	and	and	CCONJ
dpc-4183	1	5	conceptual	conceptual	ADJ
dpc-4183	1	6	original	original	ADJ
dpc-4183	1	7	article	article	NOUN
dpc-4183	1	8	|	|	ADV
dpc-4183	1	9	dermatol	dermatol	ADJ
dpc-4183	1	10	pract	pract	NOUN
dpc-4183	1	11	concept	concept	NOUN
dpc-4183	1	12	.	.	PUNCT
dpc-4183	2	1	2024;14(3):e2024184	2024;14(3):e2024184	NUM
dpc-4183	2	2	1	1	NUM
dpc-4183	2	3	serum	serum	NOUN
dpc-4183	2	4	calprotectin	calprotectin	NOUN
dpc-4183	2	5	levels	level	NOUN
dpc-4183	2	6	in	in	ADP
dpc-4183	2	7	vitiligo	vitiligo	ADJ
dpc-4183	2	8	patients	patient	NOUN
dpc-4183	2	9	and	and	CCONJ
dpc-4183	2	10	disease	disease	NOUN
dpc-4183	2	11	relation	relation	PROPN
dpc-4183	2	12	tugba	tugba	PROPN
dpc-4183	2	13	atak1	atak1	PROPN
dpc-4183	2	14	,	,	PUNCT
dpc-4183	2	15	selda	selda	PROPN
dpc-4183	2	16	pelin	pelin	PROPN
dpc-4183	2	17	kartal2	kartal2	PROPN
dpc-4183	2	18	,	,	PUNCT
dpc-4183	2	19	elif	elif	VERB
dpc-4183	2	20	bengu	bengu	PROPN
dpc-4183	2	21	gungor3	gungor3	PROPN
dpc-4183	2	22	,	,	PUNCT
dpc-4183	2	23	fatma	fatma	PROPN
dpc-4183	2	24	ucar3	ucar3	NOUN
dpc-4183	2	25	1	1	NUM
dpc-4183	2	26	ministry	ministry	PROPN
dpc-4183	2	27	of	of	ADP
dpc-4183	2	28	health	health	PROPN
dpc-4183	2	29	islahiye	islahiye	PROPN
dpc-4183	2	30	state	state	NOUN
dpc-4183	2	31	hospital	hospital	NOUN
dpc-4183	2	32	,	,	PUNCT
dpc-4183	2	33	dermatology	dermatology	NOUN
dpc-4183	2	34	clinic	clinic	NOUN
dpc-4183	2	35	,	,	PUNCT
dpc-4183	2	36	gaziantep	gaziantep	PROPN
dpc-4183	2	37	,	,	PUNCT
dpc-4183	2	38	turkey	turkey	PROPN
dpc-4183	2	39	2	2	NUM
dpc-4183	2	40	etlik	etlik	PROPN
dpc-4183	2	41	city	city	NOUN
dpc-4183	2	42	hospital	hospital	NOUN
dpc-4183	2	43	,	,	PUNCT
dpc-4183	2	44	dermatology	dermatology	NOUN
dpc-4183	2	45	clinic	clinic	NOUN
dpc-4183	2	46	,	,	PUNCT
dpc-4183	2	47	ankara	ankara	PROPN
dpc-4183	2	48	,	,	PUNCT
dpc-4183	2	49	turkey	turkey	PROPN
dpc-4183	2	50	3	3	NUM
dpc-4183	2	51	university	university	PROPN
dpc-4183	2	52	of	of	ADP
dpc-4183	2	53	health	health	PROPN
dpc-4183	2	54	sciences	sciences	PROPN
dpc-4183	2	55	,	,	PUNCT
dpc-4183	2	56	dışkapı	dışkapı	PROPN
dpc-4183	2	57	yıldırım	yıldırım	PROPN
dpc-4183	2	58	beyazıt	beyazıt	PROPN
dpc-4183	2	59	training	training	NOUN
dpc-4183	2	60	and	and	CCONJ
dpc-4183	2	61	research	research	NOUN
dpc-4183	2	62	hospital	hospital	NOUN
dpc-4183	2	63	,	,	PUNCT
dpc-4183	2	64	biochemistry	biochemistry	NOUN
dpc-4183	2	65	clinic	clinic	NOUN
dpc-4183	2	66	,	,	PUNCT
dpc-4183	2	67	ankara	ankara	PROPN
dpc-4183	2	68	,	,	PUNCT
dpc-4183	2	69	turkey	turkey	PROPN
dpc-4183	2	70	key	key	ADJ
dpc-4183	2	71	words	word	NOUN
dpc-4183	2	72	:	:	PUNCT
dpc-4183	2	73	vitiligo	vitiligo	NOUN
dpc-4183	2	74	,	,	PUNCT
dpc-4183	2	75	calprotectin	calprotectin	NOUN
dpc-4183	2	76	,	,	PUNCT
dpc-4183	2	77	s100a8	s100a8	PROPN
dpc-4183	2	78	/	/	SYM
dpc-4183	2	79	a9	a9	NOUN
dpc-4183	2	80	protein	protein	NOUN
dpc-4183	2	81	,	,	PUNCT
dpc-4183	2	82	oxidative	oxidative	ADJ
dpc-4183	2	83	stress	stress	NOUN
dpc-4183	2	84	,	,	PUNCT
dpc-4183	2	85	etiology	etiology	NOUN
dpc-4183	2	86	citation	citation	NOUN
dpc-4183	2	87	:	:	PUNCT
dpc-4183	2	88	atak	atak	PROPN
dpc-4183	2	89	t	t	PROPN
dpc-4183	2	90	,	,	PUNCT
dpc-4183	2	91	kartal	kartal	PROPN
dpc-4183	2	92	sp	sp	PROPN
dpc-4183	2	93	,	,	PUNCT
dpc-4183	2	94	gungor	gungor	PROPN
dpc-4183	2	95	eb	eb	PROPN
dpc-4183	2	96	,	,	PUNCT
dpc-4183	2	97	ucar	ucar	PROPN
dpc-4183	2	98	f.	f.	PROPN
dpc-4183	2	99	serum	serum	PROPN
dpc-4183	2	100	calprotectin	calprotectin	PROPN
dpc-4183	2	101	levels	level	NOUN
dpc-4183	2	102	in	in	ADP
dpc-4183	2	103	vitiligo	vitiligo	ADJ
dpc-4183	2	104	patients	patient	NOUN
dpc-4183	2	105	and	and	CCONJ
dpc-4183	2	106	disease	disease	NOUN
dpc-4183	2	107	relation	relation	NOUN
dpc-4183	2	108	.	.	PUNCT
dpc-4183	3	1	dermatol	dermatol	NOUN
dpc-4183	3	2	pract	pract	PROPN
dpc-4183	3	3	concept	concept	NOUN
dpc-4183	3	4	.	.	PUNCT
dpc-4183	4	1	2024;14(3):e2024184	2024;14(3):e2024184	X
dpc-4183	4	2	.	.	PUNCT
dpc-4183	5	1	doi	doi	NOUN
dpc-4183	5	2	:	:	PUNCT
dpc-4183	5	3	https://doi.org/10.5826/dpc.1403a184	https://doi.org/10.5826/dpc.1403a184	PROPN
dpc-4183	5	4	accepted	accept	VERB
dpc-4183	5	5	:	:	PUNCT
dpc-4183	5	6	march	march	PROPN
dpc-4183	5	7	22	22	NUM
dpc-4183	5	8	,	,	PUNCT
dpc-4183	5	9	2024	2024	NUM
dpc-4183	5	10	;	;	PUNCT
dpc-4183	5	11	published	publish	VERB
dpc-4183	5	12	:	:	PUNCT
dpc-4183	6	1	july	july	PROPN
dpc-4183	6	2	2024	2024	NUM
dpc-4183	6	3	copyright	copyright	NOUN
dpc-4183	6	4	:	:	PUNCT
dpc-4183	6	5	©	©	PROPN
dpc-4183	6	6	2024	2024	NUM
dpc-4183	6	7	atak	atak	PROPN
dpc-4183	6	8	et	et	PROPN
dpc-4183	6	9	al	al	PROPN
dpc-4183	6	10	.	.	PUNCT
dpc-4183	7	1	this	this	PRON
dpc-4183	7	2	is	be	AUX
dpc-4183	7	3	an	an	DET
dpc-4183	7	4	open	open	ADJ
dpc-4183	7	5	-	-	PUNCT
dpc-4183	7	6	access	access	NOUN
dpc-4183	7	7	article	article	NOUN
dpc-4183	7	8	distributed	distribute	VERB
dpc-4183	7	9	under	under	ADP
dpc-4183	7	10	the	the	DET
dpc-4183	7	11	terms	term	NOUN
dpc-4183	7	12	of	of	ADP
dpc-4183	7	13	the	the	DET
dpc-4183	7	14	creative	creative	ADJ
dpc-4183	7	15	commons	common	NOUN
dpc-4183	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4183	7	17	license	license	NOUN
dpc-4183	7	18	(	(	PUNCT
dpc-4183	7	19	by	by	ADP
dpc-4183	7	20	-	-	PUNCT
dpc-4183	7	21	nc-4.0	nc-4.0	NOUN
dpc-4183	7	22	)	)	PUNCT
dpc-4183	7	23	,	,	PUNCT
dpc-4183	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4183	7	25	,	,	PUNCT
dpc-4183	7	26	which	which	PRON
dpc-4183	7	27	permits	permit	VERB
dpc-4183	7	28	unrestricted	unrestricted	ADJ
dpc-4183	7	29	noncommercial	noncommercial	ADJ
dpc-4183	7	30	use	use	NOUN
dpc-4183	7	31	,	,	PUNCT
dpc-4183	7	32	distribution	distribution	NOUN
dpc-4183	7	33	,	,	PUNCT
dpc-4183	7	34	and	and	CCONJ
dpc-4183	7	35	reproduction	reproduction	NOUN
dpc-4183	7	36	in	in	ADP
dpc-4183	7	37	any	any	DET
dpc-4183	7	38	medium	medium	NOUN
dpc-4183	7	39	,	,	PUNCT
dpc-4183	7	40	provided	provide	VERB
dpc-4183	7	41	the	the	DET
dpc-4183	7	42	original	original	ADJ
dpc-4183	7	43	authors	author	NOUN
dpc-4183	7	44	and	and	CCONJ
dpc-4183	7	45	source	source	NOUN
dpc-4183	7	46	are	be	AUX
dpc-4183	7	47	credited	credit	VERB
dpc-4183	7	48	.	.	PUNCT
dpc-4183	8	1	funding	funding	NOUN
dpc-4183	8	2	:	:	PUNCT
dpc-4183	8	3	none	none	NOUN
dpc-4183	8	4	.	.	PUNCT
dpc-4183	9	1	competing	compete	VERB
dpc-4183	9	2	interests	interest	NOUN
dpc-4183	9	3	:	:	PUNCT
dpc-4183	9	4	none	none	NOUN
dpc-4183	9	5	.	.	PUNCT
dpc-4183	10	1	authorship	authorship	NOUN
dpc-4183	10	2	:	:	PUNCT
dpc-4183	10	3	all	all	DET
dpc-4183	10	4	authors	author	NOUN
dpc-4183	10	5	have	have	AUX
dpc-4183	10	6	contributed	contribute	VERB
dpc-4183	10	7	significantly	significantly	ADV
dpc-4183	10	8	to	to	ADP
dpc-4183	10	9	this	this	DET
dpc-4183	10	10	publication	publication	NOUN
dpc-4183	10	11	.	.	PUNCT
dpc-4183	11	1	corresponding	correspond	VERB
dpc-4183	11	2	author	author	NOUN
dpc-4183	11	3	:	:	PUNCT
dpc-4183	11	4	dr	dr	PROPN
dpc-4183	11	5	tugba	tugba	PROPN
dpc-4183	11	6	atak	atak	PROPN
dpc-4183	11	7	,	,	PUNCT
dpc-4183	11	8	ministry	ministry	PROPN
dpc-4183	11	9	of	of	ADP
dpc-4183	11	10	health	health	PROPN
dpc-4183	11	11	islahiye	islahiye	PROPN
dpc-4183	11	12	state	state	NOUN
dpc-4183	11	13	hospital	hospital	NOUN
dpc-4183	11	14	,	,	PUNCT
dpc-4183	11	15	erenler	erenler	NOUN
dpc-4183	11	16	,	,	PUNCT
dpc-4183	11	17	kırmıtlı	kırmıtlı	PROPN
dpc-4183	11	18	mevkii	mevkii	PROPN
dpc-4183	11	19	,	,	PUNCT
dpc-4183	11	20	27800	27800	NUM
dpc-4183	11	21	islahiye	islahiye	PROPN
dpc-4183	11	22	/	/	SYM
dpc-4183	11	23	gaziantep	gaziantep	PROPN
dpc-4183	11	24	,	,	PUNCT
dpc-4183	11	25	turkey	turkey	PROPN
dpc-4183	11	26	.	.	PUNCT
dpc-4183	12	1	tel	tel	ADP
dpc-4183	12	2	:	:	PUNCT
dpc-4183	12	3	+905375631269	+905375631269	NUM
dpc-4183	12	4	email	email	NOUN
dpc-4183	12	5	:	:	PUNCT
dpc-4183	12	6	tugba.atak@dr.com	tugba.atak@dr.com	X
dpc-4183	13	1	introduction	introduction	NOUN
dpc-4183	13	2	:	:	PUNCT
dpc-4183	13	3	vitiligo	vitiligo	PROPN
dpc-4183	13	4	is	be	AUX
dpc-4183	13	5	characterized	characterize	VERB
dpc-4183	13	6	as	as	ADP
dpc-4183	13	7	melanocyte	melanocyte	NOUN
dpc-4183	13	8	loss	loss	NOUN
dpc-4183	13	9	in	in	ADP
dpc-4183	13	10	skin	skin	NOUN
dpc-4183	13	11	and	and	CCONJ
dpc-4183	13	12	mucous	mucous	ADJ
dpc-4183	13	13	membranes	membrane	NOUN
dpc-4183	13	14	,	,	PUNCT
dpc-4183	13	15	the	the	DET
dpc-4183	13	16	pathogenesis	pathogenesis	NOUN
dpc-4183	13	17	of	of	ADP
dpc-4183	13	18	which	which	PRON
dpc-4183	13	19	has	have	AUX
dpc-4183	13	20	not	not	PART
dpc-4183	13	21	yet	yet	ADV
dpc-4183	13	22	been	be	AUX
dpc-4183	13	23	clarified	clarify	VERB
dpc-4183	13	24	.	.	PUNCT
dpc-4183	14	1	calprotectin	calprotectin	NOUN
dpc-4183	14	2	is	be	AUX
dpc-4183	14	3	a	a	DET
dpc-4183	14	4	protein	protein	NOUN
dpc-4183	14	5	secreted	secrete	VERB
dpc-4183	14	6	from	from	ADP
dpc-4183	14	7	neutrophils	neutrophil	NOUN
dpc-4183	14	8	,	,	PUNCT
dpc-4183	14	9	monocytes	monocyte	NOUN
dpc-4183	14	10	,	,	PUNCT
dpc-4183	14	11	and	and	CCONJ
dpc-4183	14	12	dendritic	dendritic	ADJ
dpc-4183	14	13	cells	cell	NOUN
dpc-4183	14	14	which	which	PRON
dpc-4183	14	15	has	have	VERB
dpc-4183	14	16	an	an	DET
dpc-4183	14	17	effect	effect	NOUN
dpc-4183	14	18	on	on	ADP
dpc-4183	14	19	cytokine	cytokine	ADJ
dpc-4183	14	20	receptor	receptor	NOUN
dpc-4183	14	21	regulation	regulation	NOUN
dpc-4183	14	22	and	and	CCONJ
dpc-4183	14	23	the	the	DET
dpc-4183	14	24	production	production	NOUN
dpc-4183	14	25	of	of	ADP
dpc-4183	14	26	reactive	reactive	ADJ
dpc-4183	14	27	oxygen	oxygen	NOUN
dpc-4183	14	28	radicals	radical	NOUN
dpc-4183	14	29	.	.	PUNCT
dpc-4183	15	1	it	it	PRON
dpc-4183	15	2	has	have	AUX
dpc-4183	15	3	been	be	AUX
dpc-4183	15	4	the	the	DET
dpc-4183	15	5	subject	subject	NOUN
dpc-4183	15	6	of	of	ADP
dpc-4183	15	7	research	research	NOUN
dpc-4183	15	8	in	in	ADP
dpc-4183	15	9	various	various	ADJ
dpc-4183	15	10	inflammatory	inflammatory	ADJ
dpc-4183	15	11	and	and	CCONJ
dpc-4183	15	12	autoimmune	autoimmune	ADJ
dpc-4183	15	13	diseases	disease	NOUN
dpc-4183	15	14	,	,	PUNCT
dpc-4183	15	15	yet	yet	ADV
dpc-4183	15	16	not	not	PART
dpc-4183	15	17	investigated	investigate	VERB
dpc-4183	15	18	in	in	ADP
dpc-4183	15	19	vitiligo	vitiligo	NOUN
dpc-4183	15	20	.	.	PUNCT
dpc-4183	16	1	objective	objective	NOUN
dpc-4183	16	2	:	:	PUNCT
dpc-4183	16	3	the	the	DET
dpc-4183	16	4	aim	aim	NOUN
dpc-4183	16	5	of	of	ADP
dpc-4183	16	6	our	our	PRON
dpc-4183	16	7	study	study	NOUN
dpc-4183	16	8	was	be	AUX
dpc-4183	16	9	to	to	PART
dpc-4183	16	10	investigate	investigate	VERB
dpc-4183	16	11	the	the	DET
dpc-4183	16	12	role	role	NOUN
dpc-4183	16	13	of	of	ADP
dpc-4183	16	14	calprotectin	calprotectin	NOUN
dpc-4183	16	15	in	in	ADP
dpc-4183	16	16	the	the	DET
dpc-4183	16	17	etiopathogenesis	etiopathogenesis	NOUN
dpc-4183	16	18	of	of	ADP
dpc-4183	16	19	 	 	SPACE
dpc-4183	16	20	vitiligo	vitiligo	NOUN
dpc-4183	16	21	and	and	CCONJ
dpc-4183	16	22	its	its	PRON
dpc-4183	16	23	relationship	relationship	NOUN
dpc-4183	16	24	with	with	ADP
dpc-4183	16	25	clinical	clinical	ADJ
dpc-4183	16	26	subtypes	subtype	NOUN
dpc-4183	16	27	and	and	CCONJ
dpc-4183	16	28	disease	disease	NOUN
dpc-4183	16	29	scores	score	NOUN
dpc-4183	16	30	.	.	PUNCT
dpc-4183	17	1	methods	method	NOUN
dpc-4183	17	2	:	:	PUNCT
dpc-4183	17	3	forty	forty	NUM
dpc-4183	17	4	-	-	PUNCT
dpc-4183	17	5	four	four	NUM
dpc-4183	17	6	vitiligo	vitiligo	NOUN
dpc-4183	17	7	patients	patient	NOUN
dpc-4183	17	8	with	with	ADP
dpc-4183	17	9	lack	lack	NOUN
dpc-4183	17	10	of	of	ADP
dpc-4183	17	11	autoimmune	autoimmune	ADJ
dpc-4183	17	12	disease	disease	NOUN
dpc-4183	17	13	and	and	CCONJ
dpc-4183	17	14	36	36	NUM
dpc-4183	17	15	ageand	ageand	NOUN
dpc-4183	17	16	sex	sex	NOUN
dpc-4183	17	17	-	-	PUNCT
dpc-4183	17	18	matched	match	VERB
dpc-4183	17	19	healthy	healthy	ADJ
dpc-4183	17	20	controls	control	NOUN
dpc-4183	17	21	were	be	AUX
dpc-4183	17	22	involved	involve	VERB
dpc-4183	17	23	in	in	ADP
dpc-4183	17	24	the	the	DET
dpc-4183	17	25	study	study	NOUN
dpc-4183	17	26	.	.	PUNCT
dpc-4183	18	1	serum	serum	PROPN
dpc-4183	18	2	calprotectin	calprotectin	NOUN
dpc-4183	18	3	levels	level	NOUN
dpc-4183	18	4	were	be	AUX
dpc-4183	18	5	measured	measure	VERB
dpc-4183	18	6	by	by	ADP
dpc-4183	18	7	elisa	elisa	PROPN
dpc-4183	18	8	.	.	PUNCT
dpc-4183	19	1	the	the	DET
dpc-4183	19	2	results	result	NOUN
dpc-4183	19	3	were	be	AUX
dpc-4183	19	4	compared	compare	VERB
dpc-4183	19	5	with	with	ADP
dpc-4183	19	6	the	the	DET
dpc-4183	19	7	control	control	NOUN
dpc-4183	19	8	group	group	NOUN
dpc-4183	19	9	,	,	PUNCT
dpc-4183	19	10	and	and	CCONJ
dpc-4183	19	11	the	the	DET
dpc-4183	19	12	relationship	relationship	NOUN
dpc-4183	19	13	between	between	ADP
dpc-4183	19	14	patients	patient	NOUN
dpc-4183	19	15	’	’	PART
dpc-4183	19	16	demographic	demographic	ADJ
dpc-4183	19	17	characteristics	characteristic	NOUN
dpc-4183	19	18	,	,	PUNCT
dpc-4183	19	19	skin	skin	NOUN
dpc-4183	19	20	phototypes	phototype	NOUN
dpc-4183	19	21	,	,	PUNCT
dpc-4183	19	22	disease	disease	NOUN
dpc-4183	19	23	type	type	NOUN
dpc-4183	19	24	,	,	PUNCT
dpc-4183	19	25	disease	disease	NOUN
dpc-4183	19	26	scores	score	NOUN
dpc-4183	19	27	(	(	PUNCT
dpc-4183	19	28	vitiligo	vitiligo	NOUN
dpc-4183	19	29	area	area	NOUN
dpc-4183	19	30	scoring	scoring	NOUN
dpc-4183	19	31	index	index	NOUN
dpc-4183	19	32	and	and	CCONJ
dpc-4183	19	33	vitiligo	vitiligo	NOUN
dpc-4183	19	34	disease	disease	NOUN
dpc-4183	19	35	activity	activity	NOUN
dpc-4183	19	36	score	score	NOUN
dpc-4183	19	37	)	)	PUNCT
dpc-4183	19	38	,	,	PUNCT
dpc-4183	19	39	disease	disease	NOUN
dpc-4183	19	40	duration	duration	NOUN
dpc-4183	19	41	,	,	PUNCT
dpc-4183	19	42	and	and	CCONJ
dpc-4183	19	43	age	age	NOUN
dpc-4183	19	44	at	at	ADP
dpc-4183	19	45	onset	onset	NOUN
dpc-4183	19	46	were	be	AUX
dpc-4183	19	47	evaluated	evaluate	VERB
dpc-4183	19	48	.	.	PUNCT
dpc-4183	20	1	results	result	NOUN
dpc-4183	20	2	:	:	PUNCT
dpc-4183	20	3	the	the	DET
dpc-4183	20	4	median	median	ADJ
dpc-4183	20	5	serum	serum	NOUN
dpc-4183	20	6	calprotectin	calprotectin	NOUN
dpc-4183	20	7	level	level	NOUN
dpc-4183	20	8	was	be	AUX
dpc-4183	20	9	454.08	454.08	NUM
dpc-4183	20	10	pg	pg	NOUN
dpc-4183	20	11	/	/	SYM
dpc-4183	20	12	ml	ml	PROPN
dpc-4183	20	13	(	(	PUNCT
dpc-4183	20	14	41.19–873.41	41.19–873.41	NUM
dpc-4183	20	15	)	)	PUNCT
dpc-4183	20	16	in	in	ADP
dpc-4183	20	17	the	the	DET
dpc-4183	20	18	patient	patient	NOUN
dpc-4183	20	19	group	group	NOUN
dpc-4183	20	20	,	,	PUNCT
dpc-4183	20	21	and	and	CCONJ
dpc-4183	20	22	the	the	DET
dpc-4183	20	23	median	median	ADJ
dpc-4183	20	24	serum	serum	NOUN
dpc-4183	20	25	calprotectin	calprotectin	NOUN
dpc-4183	20	26	level	level	NOUN
dpc-4183	20	27	was	be	AUX
dpc-4183	20	28	223.17	223.17	NUM
dpc-4183	20	29	pg	pg	NOUN
dpc-4183	20	30	/	/	SYM
dpc-4183	20	31	ml	ml	PROPN
dpc-4183	20	32	(	(	PUNCT
dpc-4183	20	33	44.88–1044.43	44.88–1044.43	NOUN
dpc-4183	20	34	)	)	PUNCT
dpc-4183	20	35	in	in	ADP
dpc-4183	20	36	the	the	DET
dpc-4183	20	37	control	control	NOUN
dpc-4183	20	38	group	group	NOUN
dpc-4183	20	39	.	.	PUNCT
dpc-4183	21	1	serum	serum	NOUN
dpc-4183	21	2	calprotectin	calprotectin	NOUN
dpc-4183	21	3	level	level	NOUN
dpc-4183	21	4	was	be	AUX
dpc-4183	21	5	significantly	significantly	ADV
dpc-4183	21	6	higher	high	ADJ
dpc-4183	21	7	in	in	ADP
dpc-4183	21	8	the	the	DET
dpc-4183	21	9	patient	patient	ADJ
dpc-4183	21	10	group	group	NOUN
dpc-4183	21	11	than	than	ADP
dpc-4183	21	12	in	in	ADP
dpc-4183	21	13	the	the	DET
dpc-4183	21	14	control	control	NOUN
dpc-4183	21	15	group	group	NOUN
dpc-4183	21	16	 	 	SPACE
dpc-4183	21	17	(	(	PUNCT
dpc-4183	21	18	p	p	X
dpc-4183	21	19	 	 	SPACE
dpc-4183	21	20	=	=	NOUN
dpc-4183	21	21	 	 	SPACE
dpc-4183	21	22	0.016	0.016	NUM
dpc-4183	21	23	)	)	PUNCT
dpc-4183	21	24	.	.	PUNCT
dpc-4183	22	1	no	no	DET
dpc-4183	22	2	correlation	correlation	NOUN
dpc-4183	22	3	was	be	AUX
dpc-4183	22	4	found	find	VERB
dpc-4183	22	5	between	between	ADP
dpc-4183	22	6	serum	serum	NOUN
dpc-4183	22	7	calprotectin	calprotectin	NOUN
dpc-4183	22	8	level	level	NOUN
dpc-4183	22	9	and	and	CCONJ
dpc-4183	22	10	disease	disease	NOUN
dpc-4183	22	11	scores	score	NOUN
dpc-4183	22	12	,	,	PUNCT
dpc-4183	22	13	disease	disease	NOUN
dpc-4183	22	14	duration	duration	NOUN
dpc-4183	22	15	,	,	PUNCT
dpc-4183	22	16	age	age	NOUN
dpc-4183	22	17	,	,	PUNCT
dpc-4183	22	18	or	or	CCONJ
dpc-4183	22	19	age	age	NOUN
dpc-4183	22	20	of	of	ADP
dpc-4183	22	21	onset	onset	NOUN
dpc-4183	22	22	of	of	ADP
dpc-4183	22	23	disease	disease	NOUN
dpc-4183	22	24	(	(	PUNCT
dpc-4183	22	25	p	p	NOUN
dpc-4183	22	26	˃	˃	NOUN
dpc-4183	22	27	0.05	0.05	NUM
dpc-4183	22	28	)	)	PUNCT
dpc-4183	22	29	.	.	PUNCT
dpc-4183	23	1	conclusions	conclusion	NOUN
dpc-4183	23	2	:	:	PUNCT
dpc-4183	23	3	in	in	ADP
dpc-4183	23	4	our	our	PRON
dpc-4183	23	5	study	study	NOUN
dpc-4183	23	6	,	,	PUNCT
dpc-4183	23	7	serum	serum	NOUN
dpc-4183	23	8	calprotectin	calprotectin	NOUN
dpc-4183	23	9	levels	level	NOUN
dpc-4183	23	10	in	in	ADP
dpc-4183	23	11	the	the	DET
dpc-4183	23	12	patient	patient	NOUN
dpc-4183	23	13	group	group	NOUN
dpc-4183	23	14	were	be	AUX
dpc-4183	23	15	found	find	VERB
dpc-4183	23	16	to	to	PART
dpc-4183	23	17	be	be	AUX
dpc-4183	23	18	significantly	significantly	ADV
dpc-4183	23	19	higher	high	ADJ
dpc-4183	23	20	than	than	ADP
dpc-4183	23	21	in	in	ADP
dpc-4183	23	22	the	the	DET
dpc-4183	23	23	control	control	NOUN
dpc-4183	23	24	group	group	NOUN
dpc-4183	23	25	.	.	PUNCT
dpc-4183	24	1	our	our	PRON
dpc-4183	24	2	findings	finding	NOUN
dpc-4183	24	3	and	and	CCONJ
dpc-4183	24	4	the	the	DET
dpc-4183	24	5	existing	exist	VERB
dpc-4183	24	6	literature	literature	NOUN
dpc-4183	24	7	on	on	ADP
dpc-4183	24	8	calprotectin	calprotectin	NOUN
dpc-4183	24	9	suggest	suggest	VERB
dpc-4183	24	10	its	its	PRON
dpc-4183	24	11	potential	potential	ADJ
dpc-4183	24	12	involvement	involvement	NOUN
dpc-4183	24	13	in	in	ADP
dpc-4183	24	14	the	the	DET
dpc-4183	24	15	pathogenesis	pathogenesis	NOUN
dpc-4183	24	16	of	of	ADP
dpc-4183	24	17	vitiligo	vitiligo	NOUN
dpc-4183	24	18	,	,	PUNCT
dpc-4183	24	19	independent	independent	ADJ
dpc-4183	24	20	of	of	ADP
dpc-4183	24	21	disease	disease	NOUN
dpc-4183	24	22	progression	progression	NOUN
dpc-4183	24	23	and	and	CCONJ
dpc-4183	24	24	patient	patient	ADJ
dpc-4183	24	25	characteristics	characteristic	NOUN
dpc-4183	24	26	.	.	PUNCT
dpc-4183	25	1	abstract	abstract	ADJ
dpc-4183	25	2	2	2	NUM
dpc-4183	25	3	original	original	ADJ
dpc-4183	25	4	article	article	NOUN
dpc-4183	25	5	|	|	ADV
dpc-4183	25	6	dermatol	dermatol	ADJ
dpc-4183	25	7	pract	pract	NOUN
dpc-4183	25	8	concept	concept	NOUN
dpc-4183	25	9	.	.	PUNCT
dpc-4183	26	1	2024;14(3):e2024184	2024;14(3):e2024184	NUM
dpc-4183	26	2	introduction	introduction	NOUN
dpc-4183	26	3	vitiligo	vitiligo	NOUN
dpc-4183	26	4	is	be	AUX
dpc-4183	26	5	an	an	DET
dpc-4183	26	6	acquired	acquire	VERB
dpc-4183	26	7	skin	skin	NOUN
dpc-4183	26	8	and	and	CCONJ
dpc-4183	26	9	mucous	mucous	ADJ
dpc-4183	26	10	disease	disease	NOUN
dpc-4183	26	11	that	that	PRON
dpc-4183	26	12	occurs	occur	VERB
dpc-4183	26	13	as	as	ADP
dpc-4183	26	14	a	a	DET
dpc-4183	26	15	result	result	NOUN
dpc-4183	26	16	of	of	ADP
dpc-4183	26	17	selective	selective	ADJ
dpc-4183	26	18	loss	loss	NOUN
dpc-4183	26	19	of	of	ADP
dpc-4183	26	20	melanocytes	melanocyte	NOUN
dpc-4183	26	21	and	and	CCONJ
dpc-4183	26	22	is	be	AUX
dpc-4183	26	23	characterized	characterize	VERB
dpc-4183	26	24	by	by	ADP
dpc-4183	26	25	well	well	ADV
dpc-4183	26	26	-	-	PUNCT
dpc-4183	26	27	circumscribed	circumscribe	VERB
dpc-4183	26	28	depigmented	depigmented	ADJ
dpc-4183	26	29	macula	macula	NOUN
dpc-4183	26	30	or	or	CCONJ
dpc-4183	26	31	patches	patch	NOUN
dpc-4183	26	32	.	.	PUNCT
dpc-4183	27	1	it	it	PRON
dpc-4183	27	2	can	can	AUX
dpc-4183	27	3	be	be	AUX
dpc-4183	27	4	seen	see	VERB
dpc-4183	27	5	at	at	ADP
dpc-4183	27	6	any	any	DET
dpc-4183	27	7	age	age	NOUN
dpc-4183	27	8	and	and	CCONJ
dpc-4183	27	9	can	can	AUX
dpc-4183	27	10	cause	cause	VERB
dpc-4183	27	11	psychological	psychological	ADJ
dpc-4183	27	12	problems	problem	NOUN
dpc-4183	27	13	due	due	ADJ
dpc-4183	27	14	to	to	ADP
dpc-4183	27	15	cosmetic	cosmetic	ADJ
dpc-4183	27	16	appearance	appearance	NOUN
dpc-4183	28	1	[	[	X
dpc-4183	28	2	1	1	NUM
dpc-4183	28	3	-	-	SYM
dpc-4183	28	4	4	4	NUM
dpc-4183	28	5	]	]	PUNCT
dpc-4183	28	6	.	.	PUNCT
dpc-4183	29	1	the	the	DET
dpc-4183	29	2	etiology	etiology	NOUN
dpc-4183	29	3	of	of	ADP
dpc-4183	29	4	vitiligo	vitiligo	NOUN
dpc-4183	29	5	is	be	AUX
dpc-4183	29	6	unknown	unknown	ADJ
dpc-4183	29	7	.	.	PUNCT
dpc-4183	30	1	some	some	PRON
dpc-4183	30	2	of	of	ADP
dpc-4183	30	3	the	the	DET
dpc-4183	30	4	prevalent	prevalent	ADJ
dpc-4183	30	5	hypotheses	hypothesis	NOUN
dpc-4183	30	6	,	,	PUNCT
dpc-4183	30	7	including	include	VERB
dpc-4183	30	8	the	the	DET
dpc-4183	30	9	autoimmune	autoimmune	ADJ
dpc-4183	30	10	,	,	PUNCT
dpc-4183	30	11	genetic	genetic	ADJ
dpc-4183	30	12	,	,	PUNCT
dpc-4183	30	13	oxidative	oxidative	ADJ
dpc-4183	30	14	stress	stress	NOUN
dpc-4183	30	15	,	,	PUNCT
dpc-4183	30	16	neural	neural	ADJ
dpc-4183	30	17	,	,	PUNCT
dpc-4183	30	18	cytotoxic	cytotoxic	ADJ
dpc-4183	30	19	,	,	PUNCT
dpc-4183	30	20	and	and	CCONJ
dpc-4183	30	21	metabolic	metabolic	NOUN
dpc-4183	30	22	etiologies	etiology	NOUN
dpc-4183	30	23	,	,	PUNCT
dpc-4183	30	24	have	have	AUX
dpc-4183	30	25	been	be	AUX
dpc-4183	30	26	suggested	suggest	VERB
dpc-4183	30	27	[	[	X
dpc-4183	30	28	5	5	NUM
dpc-4183	30	29	]	]	PUNCT
dpc-4183	30	30	.	.	PUNCT
dpc-4183	31	1	a	a	DET
dpc-4183	31	2	recent	recent	ADJ
dpc-4183	31	3	study	study	NOUN
dpc-4183	31	4	identified	identify	VERB
dpc-4183	31	5	key	key	ADJ
dpc-4183	31	6	genes	gene	NOUN
dpc-4183	31	7	that	that	PRON
dpc-4183	31	8	may	may	AUX
dpc-4183	31	9	play	play	VERB
dpc-4183	31	10	a	a	DET
dpc-4183	31	11	role	role	NOUN
dpc-4183	31	12	in	in	ADP
dpc-4183	31	13	pathogenesis	pathogenesis	NOUN
dpc-4183	31	14	.	.	PUNCT
dpc-4183	32	1	these	these	DET
dpc-4183	32	2	genes	gene	NOUN
dpc-4183	32	3	,	,	PUNCT
dpc-4183	32	4	including	include	VERB
dpc-4183	32	5	s100a8	s100a8	PROPN
dpc-4183	32	6	,	,	PUNCT
dpc-4183	32	7	s100a9	s100a9	NOUN
dpc-4183	32	8	,	,	PUNCT
dpc-4183	32	9	muc-1	muc-1	NOUN
dpc-4183	32	10	,	,	PUNCT
dpc-4183	32	11	and	and	CCONJ
dpc-4183	32	12	pparg	pparg	NOUN
dpc-4183	32	13	,	,	PUNCT
dpc-4183	32	14	play	play	VERB
dpc-4183	32	15	a	a	DET
dpc-4183	32	16	role	role	NOUN
dpc-4183	32	17	in	in	ADP
dpc-4183	32	18	the	the	DET
dpc-4183	32	19	intrinsic	intrinsic	ADJ
dpc-4183	32	20	apoptotic	apoptotic	ADJ
dpc-4183	32	21	signaling	signal	VERB
dpc-4183	32	22	pathway	pathway	NOUN
dpc-4183	32	23	.	.	PUNCT
dpc-4183	33	1	it	it	PRON
dpc-4183	33	2	is	be	AUX
dpc-4183	33	3	known	know	VERB
dpc-4183	33	4	that	that	SCONJ
dpc-4183	33	5	epidermal	epidermal	ADJ
dpc-4183	33	6	melanocytes	melanocyte	NOUN
dpc-4183	33	7	are	be	AUX
dpc-4183	33	8	affected	affect	VERB
dpc-4183	33	9	by	by	ADP
dpc-4183	33	10	radical	radical	ADJ
dpc-4183	33	11	oxygen	oxygen	NOUN
dpc-4183	33	12	radicals	radical	NOUN
dpc-4183	33	13	,	,	PUNCT
dpc-4183	33	14	and	and	CCONJ
dpc-4183	33	15	it	it	PRON
dpc-4183	33	16	is	be	AUX
dpc-4183	33	17	thought	think	VERB
dpc-4183	33	18	that	that	SCONJ
dpc-4183	33	19	apoptosis	apoptosis	NOUN
dpc-4183	33	20	caused	cause	VERB
dpc-4183	33	21	by	by	ADP
dpc-4183	33	22	radical	radical	ADJ
dpc-4183	33	23	oxygen	oxygen	NOUN
dpc-4183	33	24	radicals	radical	NOUN
dpc-4183	33	25	may	may	AUX
dpc-4183	33	26	be	be	AUX
dpc-4183	33	27	responsible	responsible	ADJ
dpc-4183	33	28	for	for	ADP
dpc-4183	33	29	melanocyte	melanocyte	NOUN
dpc-4183	33	30	loss	loss	NOUN
dpc-4183	34	1	[	[	X
dpc-4183	34	2	6	6	NUM
dpc-4183	34	3	]	]	PUNCT
dpc-4183	34	4	.	.	PUNCT
dpc-4183	35	1	calprotectin	calprotectin	NOUN
dpc-4183	35	2	is	be	AUX
dpc-4183	35	3	secreted	secrete	VERB
dpc-4183	35	4	by	by	ADP
dpc-4183	35	5	neutrophils	neutrophil	NOUN
dpc-4183	35	6	,	,	PUNCT
dpc-4183	35	7	monocytes	monocyte	NOUN
dpc-4183	35	8	,	,	PUNCT
dpc-4183	35	9	and	and	CCONJ
dpc-4183	35	10	dendritic	dendritic	ADJ
dpc-4183	35	11	cells	cell	NOUN
dpc-4183	35	12	and	and	CCONJ
dpc-4183	35	13	consists	consist	VERB
dpc-4183	35	14	of	of	ADP
dpc-4183	35	15	a	a	DET
dpc-4183	35	16	heterodimeric	heterodimeric	ADJ
dpc-4183	35	17	complex	complex	NOUN
dpc-4183	35	18	of	of	ADP
dpc-4183	35	19	two	two	NUM
dpc-4183	35	20	proteins	protein	NOUN
dpc-4183	35	21	,	,	PUNCT
dpc-4183	35	22	s100a8	s100a8	PROPN
dpc-4183	35	23	and	and	CCONJ
dpc-4183	35	24	s100a9	s100a9	PROPN
dpc-4183	36	1	[	[	X
dpc-4183	36	2	7	7	NUM
dpc-4183	36	3	,	,	PUNCT
dpc-4183	36	4	8	8	NUM
dpc-4183	36	5	]	]	PUNCT
dpc-4183	36	6	.	.	PUNCT
dpc-4183	37	1	when	when	SCONJ
dpc-4183	37	2	released	release	VERB
dpc-4183	37	3	,	,	PUNCT
dpc-4183	37	4	it	it	PRON
dpc-4183	37	5	has	have	VERB
dpc-4183	37	6	functions	function	NOUN
dpc-4183	37	7	such	such	ADJ
dpc-4183	37	8	as	as	ADP
dpc-4183	37	9	damage	damage	NOUN
dpc-4183	37	10	-	-	PUNCT
dpc-4183	37	11	associated	associate	VERB
dpc-4183	37	12	pattern	pattern	NOUN
dpc-4183	37	13	molecule	molecule	NOUN
dpc-4183	37	14	(	(	PUNCT
dpc-4183	37	15	damp	damp	NOUN
dpc-4183	37	16	)	)	PUNCT
dpc-4183	37	17	or	or	CCONJ
dpc-4183	37	18	function	function	NOUN
dpc-4183	37	19	as	as	ADP
dpc-4183	37	20	alarmin	alarmin	NOUN
dpc-4183	37	21	and	and	CCONJ
dpc-4183	37	22	promoting	promote	VERB
dpc-4183	37	23	inflammatory	inflammatory	ADJ
dpc-4183	37	24	response	response	NOUN
dpc-4183	37	25	[	[	X
dpc-4183	37	26	9	9	NUM
dpc-4183	37	27	]	]	PUNCT
dpc-4183	37	28	.	.	PUNCT
dpc-4183	38	1	it	it	PRON
dpc-4183	38	2	have	have	AUX
dpc-4183	38	3	been	be	AUX
dpc-4183	38	4	thought	think	VERB
dpc-4183	38	5	that	that	SCONJ
dpc-4183	38	6	alarmins	alarmin	NOUN
dpc-4183	38	7	are	be	AUX
dpc-4183	38	8	also	also	ADV
dpc-4183	38	9	released	release	VERB
dpc-4183	38	10	in	in	ADP
dpc-4183	38	11	response	response	NOUN
dpc-4183	38	12	to	to	ADP
dpc-4183	38	13	cell	cell	NOUN
dpc-4183	38	14	injury	injury	NOUN
dpc-4183	38	15	or	or	CCONJ
dpc-4183	38	16	death	death	NOUN
dpc-4183	38	17	.	.	PUNCT
dpc-4183	39	1	they	they	PRON
dpc-4183	39	2	activate	activate	VERB
dpc-4183	39	3	immune	immune	ADJ
dpc-4183	39	4	cells	cell	NOUN
dpc-4183	39	5	both	both	CCONJ
dpc-4183	39	6	in	in	ADP
dpc-4183	39	7	host	host	NOUN
dpc-4183	39	8	defence	defence	NOUN
dpc-4183	39	9	and	and	CCONJ
dpc-4183	39	10	in	in	ADP
dpc-4183	39	11	disease	disease	NOUN
dpc-4183	39	12	.	.	PUNCT
dpc-4183	40	1	s100a8/	s100a8/	VERB
dpc-4183	40	2	s100a9	s100a9	ADJ
dpc-4183	40	3	,	,	PUNCT
dpc-4183	40	4	as	as	ADP
dpc-4183	40	5	alarmins	alarmin	NOUN
dpc-4183	40	6	,	,	PUNCT
dpc-4183	40	7	tend	tend	VERB
dpc-4183	40	8	to	to	PART
dpc-4183	40	9	rise	rise	VERB
dpc-4183	40	10	after	after	ADP
dpc-4183	40	11	oxidative	oxidative	ADJ
dpc-4183	40	12	stress	stress	NOUN
dpc-4183	40	13	and	and	CCONJ
dpc-4183	40	14	cell	cell	NOUN
dpc-4183	40	15	death	death	NOUN
dpc-4183	40	16	and	and	CCONJ
dpc-4183	40	17	are	be	AUX
dpc-4183	40	18	then	then	ADV
dpc-4183	40	19	involved	involve	VERB
dpc-4183	40	20	in	in	ADP
dpc-4183	40	21	the	the	DET
dpc-4183	40	22	aberrant	aberrant	ADJ
dpc-4183	40	23	immune	immune	ADJ
dpc-4183	40	24	response	response	NOUN
dpc-4183	41	1	[	[	X
dpc-4183	41	2	10	10	NUM
dpc-4183	41	3	]	]	PUNCT
dpc-4183	41	4	.	.	PUNCT
dpc-4183	42	1	calprotectin	calprotectin	NOUN
dpc-4183	42	2	’s	’s	PART
dpc-4183	42	3	effect	effect	NOUN
dpc-4183	42	4	on	on	ADP
dpc-4183	42	5	cytokine	cytokine	ADJ
dpc-4183	42	6	receptor	receptor	NOUN
dpc-4183	42	7	regulation	regulation	NOUN
dpc-4183	42	8	and	and	CCONJ
dpc-4183	42	9	its	its	PRON
dpc-4183	42	10	role	role	NOUN
dpc-4183	42	11	in	in	ADP
dpc-4183	42	12	the	the	DET
dpc-4183	42	13	production	production	NOUN
dpc-4183	42	14	of	of	ADP
dpc-4183	42	15	reactive	reactive	ADJ
dpc-4183	42	16	oxygen	oxygen	NOUN
dpc-4183	42	17	radicals	radical	NOUN
dpc-4183	42	18	are	be	AUX
dpc-4183	42	19	important	important	ADJ
dpc-4183	42	20	in	in	ADP
dpc-4183	42	21	chronic	chronic	ADJ
dpc-4183	42	22	inflammatory	inflammatory	ADJ
dpc-4183	42	23	diseases	disease	NOUN
dpc-4183	42	24	[	[	X
dpc-4183	42	25	8	8	NUM
dpc-4183	42	26	]	]	PUNCT
dpc-4183	42	27	.	.	PUNCT
dpc-4183	43	1	since	since	SCONJ
dpc-4183	43	2	dendritic	dendritic	ADJ
dpc-4183	43	3	cells	cell	NOUN
dpc-4183	43	4	and	and	CCONJ
dpc-4183	43	5	cytotoxic	cytotoxic	ADJ
dpc-4183	43	6	t	t	NOUN
dpc-4183	43	7	cells	cell	NOUN
dpc-4183	43	8	are	be	AUX
dpc-4183	43	9	involved	involve	VERB
dpc-4183	43	10	in	in	ADP
dpc-4183	43	11	melanocyte	melanocyte	ADJ
dpc-4183	43	12	destruction	destruction	NOUN
dpc-4183	43	13	in	in	ADP
dpc-4183	43	14	the	the	DET
dpc-4183	43	15	autoimmune	autoimmune	ADJ
dpc-4183	43	16	hypothesis	hypothesis	NOUN
dpc-4183	43	17	in	in	ADP
dpc-4183	43	18	vitiligo	vitiligo	NOUN
dpc-4183	43	19	pathogenesis	pathogenesis	NOUN
dpc-4183	43	20	,	,	PUNCT
dpc-4183	43	21	the	the	DET
dpc-4183	43	22	aim	aim	NOUN
dpc-4183	43	23	of	of	ADP
dpc-4183	43	24	this	this	DET
dpc-4183	43	25	study	study	NOUN
dpc-4183	43	26	was	be	AUX
dpc-4183	43	27	to	to	PART
dpc-4183	43	28	examine	examine	VERB
dpc-4183	43	29	the	the	DET
dpc-4183	43	30	role	role	NOUN
dpc-4183	43	31	of	of	ADP
dpc-4183	43	32	calprotectin	calprotectin	NOUN
dpc-4183	43	33	in	in	ADP
dpc-4183	43	34	the	the	DET
dpc-4183	43	35	pathogenesis	pathogenesis	NOUN
dpc-4183	43	36	of	of	ADP
dpc-4183	43	37	the	the	DET
dpc-4183	43	38	disease	disease	NOUN
dpc-4183	43	39	and	and	CCONJ
dpc-4183	43	40	to	to	PART
dpc-4183	43	41	determine	determine	VERB
dpc-4183	43	42	whether	whether	SCONJ
dpc-4183	43	43	this	this	DET
dpc-4183	43	44	protein	protein	NOUN
dpc-4183	43	45	is	be	AUX
dpc-4183	43	46	associated	associate	VERB
dpc-4183	43	47	with	with	ADP
dpc-4183	43	48	clinical	clinical	ADJ
dpc-4183	43	49	subtypes	subtype	NOUN
dpc-4183	43	50	and	and	CCONJ
dpc-4183	43	51	disease	disease	NOUN
dpc-4183	43	52	scores	score	NOUN
dpc-4183	43	53	.	.	PUNCT
dpc-4183	44	1	material	material	NOUN
dpc-4183	44	2	and	and	CCONJ
dpc-4183	44	3	methods	method	NOUN
dpc-4183	44	4	forty	forty	NUM
dpc-4183	44	5	-	-	PUNCT
dpc-4183	44	6	four	four	NUM
dpc-4183	44	7	vitiligo	vitiligo	NOUN
dpc-4183	44	8	patients	patient	NOUN
dpc-4183	44	9	(	(	PUNCT
dpc-4183	44	10	age	age	NOUN
dpc-4183	44	11	18	18	NUM
dpc-4183	44	12	-	-	SYM
dpc-4183	44	13	65	65	NUM
dpc-4183	44	14	years	year	NOUN
dpc-4183	44	15	,	,	PUNCT
dpc-4183	44	16	without	without	ADP
dpc-4183	44	17	inflammatory	inflammatory	ADJ
dpc-4183	44	18	infectious	infectious	ADJ
dpc-4183	44	19	,	,	PUNCT
dpc-4183	44	20	other	other	ADJ
dpc-4183	44	21	autoimmune	autoimmune	ADJ
dpc-4183	44	22	diseases	disease	NOUN
dpc-4183	44	23	or	or	CCONJ
dpc-4183	44	24	malignancy	malignancy	NOUN
dpc-4183	44	25	)	)	PUNCT
dpc-4183	44	26	admitted	admit	VERB
dpc-4183	44	27	to	to	ADP
dpc-4183	44	28	our	our	PRON
dpc-4183	44	29	dermatology	dermatology	NOUN
dpc-4183	44	30	outpatient	outpatient	NOUN
dpc-4183	44	31	clinic	clinic	NOUN
dpc-4183	44	32	were	be	AUX
dpc-4183	44	33	included	include	VERB
dpc-4183	44	34	in	in	ADP
dpc-4183	44	35	the	the	DET
dpc-4183	44	36	study	study	NOUN
dpc-4183	44	37	.	.	PUNCT
dpc-4183	45	1	the	the	DET
dpc-4183	45	2	control	control	PROPN
dpc-4183	45	3	group	group	NOUN
dpc-4183	45	4	consisted	consist	VERB
dpc-4183	45	5	of	of	ADP
dpc-4183	45	6	36	36	NUM
dpc-4183	45	7	ageand	ageand	NOUN
dpc-4183	45	8	sex	sex	NOUN
dpc-4183	45	9	-	-	PUNCT
dpc-4183	45	10	matched	match	VERB
dpc-4183	45	11	healthy	healthy	ADJ
dpc-4183	45	12	volunteers	volunteer	NOUN
dpc-4183	45	13	.	.	PUNCT
dpc-4183	46	1	the	the	DET
dpc-4183	46	2	study	study	NOUN
dpc-4183	46	3	was	be	AUX
dpc-4183	46	4	conducted	conduct	VERB
dpc-4183	46	5	in	in	ADP
dpc-4183	46	6	accordance	accordance	NOUN
dpc-4183	46	7	with	with	ADP
dpc-4183	46	8	the	the	DET
dpc-4183	46	9	declaration	declaration	NOUN
dpc-4183	46	10	of	of	ADP
dpc-4183	46	11	helsinki	helsinki	PROPN
dpc-4183	46	12	guidelines	guideline	NOUN
dpc-4183	46	13	.	.	PUNCT
dpc-4183	47	1	all	all	DET
dpc-4183	47	2	participants	participant	NOUN
dpc-4183	47	3	were	be	AUX
dpc-4183	47	4	informed	inform	VERB
dpc-4183	47	5	about	about	ADP
dpc-4183	47	6	the	the	DET
dpc-4183	47	7	procedures	procedure	NOUN
dpc-4183	47	8	and	and	CCONJ
dpc-4183	47	9	their	their	PRON
dpc-4183	47	10	consent	consent	NOUN
dpc-4183	47	11	was	be	AUX
dpc-4183	47	12	obtained	obtain	VERB
dpc-4183	47	13	.	.	PUNCT
dpc-4183	48	1	patients	patient	NOUN
dpc-4183	48	2	were	be	AUX
dpc-4183	48	3	scored	score	VERB
dpc-4183	48	4	according	accord	VERB
dpc-4183	48	5	to	to	ADP
dpc-4183	48	6	vitiligo	vitiligo	NOUN
dpc-4183	48	7	area	area	NOUN
dpc-4183	48	8	scoring	scoring	NOUN
dpc-4183	48	9	index	index	NOUN
dpc-4183	48	10	(	(	PUNCT
dpc-4183	48	11	vasi	vasi	PROPN
dpc-4183	48	12	)	)	PUNCT
dpc-4183	49	1	[	[	X
dpc-4183	49	2	11	11	NUM
dpc-4183	49	3	]	]	PUNCT
dpc-4183	49	4	and	and	CCONJ
dpc-4183	49	5	vitiligo	vitiligo	NOUN
dpc-4183	49	6	disease	disease	NOUN
dpc-4183	49	7	activity	activity	NOUN
dpc-4183	49	8	score	score	NOUN
dpc-4183	49	9	(	(	PUNCT
dpc-4183	49	10	vida	vida	NOUN
dpc-4183	49	11	)	)	PUNCT
dpc-4183	50	1	[	[	X
dpc-4183	50	2	12	12	NUM
dpc-4183	50	3	,	,	PUNCT
dpc-4183	50	4	13	13	NUM
dpc-4183	50	5	]	]	PUNCT
dpc-4183	50	6	.	.	PUNCT
dpc-4183	51	1	serum	serum	PROPN
dpc-4183	51	2	calprotectin	calprotectin	PROPN
dpc-4183	51	3	levels	level	NOUN
dpc-4183	51	4	were	be	AUX
dpc-4183	51	5	compared	compare	VERB
dpc-4183	51	6	with	with	ADP
dpc-4183	51	7	the	the	DET
dpc-4183	51	8	control	control	NOUN
dpc-4183	51	9	group	group	NOUN
dpc-4183	51	10	,	,	PUNCT
dpc-4183	51	11	and	and	CCONJ
dpc-4183	51	12	the	the	DET
dpc-4183	51	13	relationship	relationship	NOUN
dpc-4183	51	14	between	between	ADP
dpc-4183	51	15	patients	patient	NOUN
dpc-4183	51	16	’	’	PART
dpc-4183	51	17	demographic	demographic	ADJ
dpc-4183	51	18	characteristics	characteristic	NOUN
dpc-4183	51	19	,	,	PUNCT
dpc-4183	51	20	skin	skin	NOUN
dpc-4183	51	21	phototypes	phototype	NOUN
dpc-4183	51	22	,	,	PUNCT
dpc-4183	51	23	disease	disease	NOUN
dpc-4183	51	24	type	type	NOUN
dpc-4183	51	25	(	(	PUNCT
dpc-4183	51	26	segmental	segmental	ADJ
dpc-4183	51	27	,	,	PUNCT
dpc-4183	51	28	generalized	generalize	VERB
dpc-4183	51	29	,	,	PUNCT
dpc-4183	51	30	focal	focal	ADJ
dpc-4183	51	31	,	,	PUNCT
dpc-4183	51	32	acrofacial	acrofacial	ADJ
dpc-4183	51	33	,	,	PUNCT
dpc-4183	51	34	universal	universal	ADJ
dpc-4183	51	35	)	)	PUNCT
dpc-4183	51	36	,	,	PUNCT
dpc-4183	51	37	presence	presence	NOUN
dpc-4183	51	38	of	of	ADP
dpc-4183	51	39	leukotrichia	leukotrichia	NOUN
dpc-4183	51	40	,	,	PUNCT
dpc-4183	51	41	treatment	treatment	NOUN
dpc-4183	51	42	status	status	NOUN
dpc-4183	51	43	in	in	ADP
dpc-4183	51	44	the	the	DET
dpc-4183	51	45	last	last	ADJ
dpc-4183	51	46	six	six	NUM
dpc-4183	51	47	months	month	NOUN
dpc-4183	51	48	,	,	PUNCT
dpc-4183	51	49	disease	disease	NOUN
dpc-4183	51	50	scores	score	NOUN
dpc-4183	51	51	,	,	PUNCT
dpc-4183	51	52	disease	disease	NOUN
dpc-4183	51	53	duration	duration	NOUN
dpc-4183	51	54	,	,	PUNCT
dpc-4183	51	55	family	family	NOUN
dpc-4183	51	56	history	history	NOUN
dpc-4183	51	57	,	,	PUNCT
dpc-4183	51	58	smoking	smoking	NOUN
dpc-4183	51	59	,	,	PUNCT
dpc-4183	51	60	body	body	NOUN
dpc-4183	51	61	mass	mass	PROPN
dpc-4183	51	62	index	index	NOUN
dpc-4183	51	63	,	,	PUNCT
dpc-4183	51	64	and	and	CCONJ
dpc-4183	51	65	age	age	NOUN
dpc-4183	51	66	at	at	ADP
dpc-4183	51	67	onset	onset	NOUN
dpc-4183	51	68	were	be	AUX
dpc-4183	51	69	evaluated	evaluate	VERB
dpc-4183	51	70	.	.	PUNCT
dpc-4183	52	1	blood	blood	NOUN
dpc-4183	52	2	samples	sample	NOUN
dpc-4183	52	3	were	be	AUX
dpc-4183	52	4	taken	take	VERB
dpc-4183	52	5	in	in	ADP
dpc-4183	52	6	serum	serum	NOUN
dpc-4183	52	7	separator	separator	NOUN
dpc-4183	52	8	tubes	tube	NOUN
dpc-4183	52	9	with	with	ADP
dpc-4183	52	10	clot	clot	NOUN
dpc-4183	52	11	activator	activator	NOUN
dpc-4183	52	12	.	.	PUNCT
dpc-4183	53	1	after	after	ADP
dpc-4183	53	2	waiting	wait	VERB
dpc-4183	53	3	for	for	ADP
dpc-4183	53	4	30	30	NUM
dpc-4183	53	5	minutes	minute	NOUN
dpc-4183	53	6	for	for	ADP
dpc-4183	53	7	coagulation	coagulation	NOUN
dpc-4183	53	8	,	,	PUNCT
dpc-4183	53	9	the	the	DET
dpc-4183	53	10	samples	sample	NOUN
dpc-4183	53	11	were	be	AUX
dpc-4183	53	12	centrifuged	centrifuge	VERB
dpc-4183	53	13	at	at	ADP
dpc-4183	53	14	1000	1000	NUM
dpc-4183	53	15	x	x	SYM
dpc-4183	53	16	g	g	NOUN
dpc-4183	53	17	for	for	ADP
dpc-4183	53	18	20	20	NUM
dpc-4183	53	19	minutes	minute	NOUN
dpc-4183	53	20	and	and	CCONJ
dpc-4183	53	21	stored	store	VERB
dpc-4183	53	22	at	at	ADP
dpc-4183	53	23	-80	-80	PUNCT
dpc-4183	53	24	ºc	ºc	PROPN
dpc-4183	53	25	until	until	ADP
dpc-4183	53	26	the	the	DET
dpc-4183	53	27	day	day	NOUN
dpc-4183	53	28	of	of	ADP
dpc-4183	53	29	analysis	analysis	NOUN
dpc-4183	53	30	.	.	PUNCT
dpc-4183	54	1	serum	serum	NOUN
dpc-4183	54	2	calprotectin	calprotectin	NOUN
dpc-4183	54	3	levels	level	NOUN
dpc-4183	54	4	were	be	AUX
dpc-4183	54	5	studied	study	VERB
dpc-4183	54	6	using	use	VERB
dpc-4183	54	7	the	the	DET
dpc-4183	54	8	cloud	cloud	ADJ
dpc-4183	54	9	clone	clone	NOUN
dpc-4183	54	10	brand	brand	NOUN
dpc-4183	54	11	(	(	PUNCT
dpc-4183	54	12	cloud	cloud	PROPN
dpc-4183	54	13	clone	clone	PROPN
dpc-4183	54	14	corp	corp	PROPN
dpc-4183	54	15	.	.	PROPN
dpc-4183	54	16	,	,	PUNCT
dpc-4183	54	17	uscn	uscn	PROPN
dpc-4183	54	18	life	life	PROPN
dpc-4183	54	19	science	science	PROPN
dpc-4183	54	20	inc	inc	PROPN
dpc-4183	54	21	.	.	PROPN
dpc-4183	54	22	,	,	PUNCT
dpc-4183	54	23	houston	houston	PROPN
dpc-4183	54	24	,	,	PUNCT
dpc-4183	54	25	tx	tx	PROPN
dpc-4183	54	26	,	,	PUNCT
dpc-4183	54	27	usa	usa	PROPN
dpc-4183	54	28	)	)	PUNCT
dpc-4183	54	29	(	(	PUNCT
dpc-4183	54	30	lot	lot	NOUN
dpc-4183	54	31	no	no	PRON
dpc-4183	54	32	:	:	PUNCT
dpc-4183	54	33	l220525461	l220525461	ADJ
dpc-4183	54	34	)	)	PUNCT
dpc-4183	54	35	mass	mass	ADJ
dpc-4183	54	36	quantitative	quantitative	ADJ
dpc-4183	54	37	enzyme	enzyme	NOUN
dpc-4183	54	38	-	-	PUNCT
dpc-4183	54	39	linked	link	VERB
dpc-4183	54	40	immunosorbent	immunosorbent	NOUN
dpc-4183	54	41	assay	assay	PROPN
dpc-4183	54	42	(	(	PUNCT
dpc-4183	54	43	elisa	elisa	NOUN
dpc-4183	54	44	)	)	PUNCT
dpc-4183	54	45	method	method	NOUN
dpc-4183	54	46	.	.	PUNCT
dpc-4183	55	1	the	the	DET
dpc-4183	55	2	measuring	measure	VERB
dpc-4183	55	3	range	range	NOUN
dpc-4183	55	4	of	of	ADP
dpc-4183	55	5	the	the	DET
dpc-4183	55	6	kit	kit	NOUN
dpc-4183	55	7	is	be	AUX
dpc-4183	55	8	31.2	31.2	NUM
dpc-4183	55	9	-	-	SYM
dpc-4183	55	10	2.000	2.000	NUM
dpc-4183	55	11	pg	pg	NOUN
dpc-4183	55	12	/	/	SYM
dpc-4183	55	13	ml	ml	PROPN
dpc-4183	55	14	,	,	PUNCT
dpc-4183	55	15	the	the	DET
dpc-4183	55	16	sensitivity	sensitivity	NOUN
dpc-4183	55	17	is	be	AUX
dpc-4183	55	18	13.6	13.6	NUM
dpc-4183	55	19	pg	pg	NOUN
dpc-4183	55	20	/	/	SYM
dpc-4183	55	21	ml	ml	NOUN
dpc-4183	55	22	within	within	ADP
dpc-4183	55	23	-	-	PUNCT
dpc-4183	55	24	run	run	NOUN
dpc-4183	55	25	coefficient	coefficient	NOUN
dpc-4183	55	26	of	of	ADP
dpc-4183	55	27	variation	variation	NOUN
dpc-4183	55	28	(	(	PUNCT
dpc-4183	55	29	cv	cv	PROPN
dpc-4183	55	30	):	):	PUNCT
dpc-4183	55	31	<	<	X
dpc-4183	55	32	10	10	NUM
dpc-4183	55	33	%	%	NOUN
dpc-4183	55	34	,	,	PUNCT
dpc-4183	55	35	between	between	ADP
dpc-4183	55	36	-	-	PUNCT
dpc-4183	55	37	study	study	NOUN
dpc-4183	55	38	coefficient	coefficient	NOUN
dpc-4183	55	39	of	of	ADP
dpc-4183	55	40	variation	variation	NOUN
dpc-4183	55	41	(	(	PUNCT
dpc-4183	55	42	cv	cv	PROPN
dpc-4183	55	43	):	):	PUNCT
dpc-4183	55	44	<	<	X
dpc-4183	55	45	12	12	NUM
dpc-4183	55	46	%	%	NOUN
dpc-4183	55	47	.	.	PUNCT
dpc-4183	56	1	the	the	DET
dpc-4183	56	2	obtained	obtain	VERB
dpc-4183	56	3	data	datum	NOUN
dpc-4183	56	4	were	be	AUX
dpc-4183	56	5	evaluated	evaluate	VERB
dpc-4183	56	6	in	in	ADP
dpc-4183	56	7	the	the	DET
dpc-4183	56	8	spss	spss	PROPN
dpc-4183	56	9	(	(	PUNCT
dpc-4183	56	10	version	version	NOUN
dpc-4183	56	11	 	 	SPACE
dpc-4183	56	12	15.0	15.0	NUM
dpc-4183	56	13	)	)	PUNCT
dpc-4183	56	14	statistical	statistical	ADJ
dpc-4183	56	15	package	package	NOUN
dpc-4183	56	16	program	program	NOUN
dpc-4183	56	17	.	.	PUNCT
dpc-4183	57	1	the	the	DET
dpc-4183	57	2	study	study	NOUN
dpc-4183	57	3	presents	present	VERB
dpc-4183	57	4	descriptive	descriptive	ADJ
dpc-4183	57	5	data	datum	NOUN
dpc-4183	57	6	using	use	VERB
dpc-4183	57	7	various	various	ADJ
dpc-4183	57	8	statistical	statistical	ADJ
dpc-4183	57	9	measures	measure	NOUN
dpc-4183	57	10	,	,	PUNCT
dpc-4183	57	11	including	include	VERB
dpc-4183	57	12	numbers	number	NOUN
dpc-4183	57	13	,	,	PUNCT
dpc-4183	57	14	percentages	percentage	NOUN
dpc-4183	57	15	,	,	PUNCT
dpc-4183	57	16	means	mean	NOUN
dpc-4183	57	17	,	,	PUNCT
dpc-4183	57	18	medians	median	NOUN
dpc-4183	57	19	,	,	PUNCT
dpc-4183	57	20	standard	standard	ADJ
dpc-4183	57	21	deviations	deviation	NOUN
dpc-4183	57	22	,	,	PUNCT
dpc-4183	57	23	and	and	CCONJ
dpc-4183	57	24	minimum	minimum	ADJ
dpc-4183	57	25	-	-	PUNCT
dpc-4183	57	26	maximum	maximum	ADJ
dpc-4183	57	27	values	value	NOUN
dpc-4183	57	28	.	.	PUNCT
dpc-4183	58	1	the	the	DET
dpc-4183	58	2	conformity	conformity	NOUN
dpc-4183	58	3	of	of	ADP
dpc-4183	58	4	the	the	DET
dpc-4183	58	5	data	datum	NOUN
dpc-4183	58	6	obtained	obtain	VERB
dpc-4183	58	7	from	from	ADP
dpc-4183	58	8	the	the	DET
dpc-4183	58	9	scales	scale	NOUN
dpc-4183	58	10	to	to	ADP
dpc-4183	58	11	the	the	DET
dpc-4183	58	12	normal	normal	ADJ
dpc-4183	58	13	distribution	distribution	NOUN
dpc-4183	58	14	was	be	AUX
dpc-4183	58	15	evaluated	evaluate	VERB
dpc-4183	58	16	with	with	ADP
dpc-4183	58	17	the	the	DET
dpc-4183	58	18	shapiro	shapiro	PROPN
dpc-4183	58	19	-	-	PUNCT
dpc-4183	58	20	wilk	wilk	NOUN
dpc-4183	58	21	test	test	NOUN
dpc-4183	58	22	.	.	PUNCT
dpc-4183	59	1	chi	chi	ADJ
dpc-4183	59	2	-	-	PUNCT
dpc-4183	59	3	square	square	PROPN
dpc-4183	59	4	test	test	NOUN
dpc-4183	59	5	was	be	AUX
dpc-4183	59	6	used	use	VERB
dpc-4183	59	7	to	to	PART
dpc-4183	59	8	compare	compare	VERB
dpc-4183	59	9	categorical	categorical	ADJ
dpc-4183	59	10	data	datum	NOUN
dpc-4183	59	11	between	between	ADP
dpc-4183	59	12	groups	group	NOUN
dpc-4183	59	13	.	.	PUNCT
dpc-4183	60	1	mann	mann	PROPN
dpc-4183	60	2	-	-	PUNCT
dpc-4183	60	3	whitney	whitney	PROPN
dpc-4183	60	4	u	u	PROPN
dpc-4183	60	5	test	test	NOUN
dpc-4183	60	6	,	,	PUNCT
dpc-4183	60	7	kruskal	kruskal	PROPN
dpc-4183	60	8	-	-	PUNCT
dpc-4183	60	9	wallis	wallis	PROPN
dpc-4183	60	10	test	test	NOUN
dpc-4183	60	11	,	,	PUNCT
dpc-4183	60	12	and	and	CCONJ
dpc-4183	60	13	spearman	spearman	NOUN
dpc-4183	60	14	’s	’s	PART
dpc-4183	60	15	correlation	correlation	NOUN
dpc-4183	60	16	analysis	analysis	NOUN
dpc-4183	60	17	were	be	AUX
dpc-4183	60	18	used	use	VERB
dpc-4183	60	19	in	in	ADP
dpc-4183	60	20	the	the	DET
dpc-4183	60	21	evaluation	evaluation	NOUN
dpc-4183	60	22	of	of	ADP
dpc-4183	60	23	the	the	DET
dpc-4183	60	24	data	datum	NOUN
dpc-4183	60	25	after	after	ADP
dpc-4183	60	26	evaluating	evaluate	VERB
dpc-4183	60	27	the	the	DET
dpc-4183	60	28	conformity	conformity	NOUN
dpc-4183	60	29	to	to	ADP
dpc-4183	60	30	the	the	DET
dpc-4183	60	31	normal	normal	ADJ
dpc-4183	60	32	distribution	distribution	NOUN
dpc-4183	60	33	.	.	PUNCT
dpc-4183	61	1	roc	roc	NOUN
dpc-4183	61	2	analysis	analysis	NOUN
dpc-4183	61	3	was	be	AUX
dpc-4183	61	4	performed	perform	VERB
dpc-4183	61	5	for	for	ADP
dpc-4183	61	6	the	the	DET
dpc-4183	61	7	distribution	distribution	NOUN
dpc-4183	61	8	of	of	ADP
dpc-4183	61	9	serum	serum	NOUN
dpc-4183	61	10	calprotectin	calprotectin	NOUN
dpc-4183	61	11	values	value	NOUN
dpc-4183	61	12	in	in	ADP
dpc-4183	61	13	the	the	DET
dpc-4183	61	14	both	both	DET
dpc-4183	61	15	groups	group	NOUN
dpc-4183	61	16	.	.	PUNCT
dpc-4183	62	1	results	result	VERB
dpc-4183	62	2	the	the	DET
dpc-4183	62	3	mean	mean	ADJ
dpc-4183	62	4	age	age	NOUN
dpc-4183	62	5	(	(	PUNCT
dpc-4183	62	6	37.38±11.78	37.38±11.78	NUM
dpc-4183	62	7	and	and	CCONJ
dpc-4183	62	8	36.75±9.12	36.75±9.12	NUM
dpc-4183	62	9	years	year	NOUN
dpc-4183	62	10	,	,	PUNCT
dpc-4183	62	11	respectively	respectively	ADV
dpc-4183	62	12	)	)	PUNCT
dpc-4183	62	13	and	and	CCONJ
dpc-4183	62	14	sex	sex	NOUN
dpc-4183	62	15	distribution	distribution	NOUN
dpc-4183	62	16	(	(	PUNCT
dpc-4183	62	17	13	13	NUM
dpc-4183	62	18	female/31	female/31	ADJ
dpc-4183	62	19	male	male	NOUN
dpc-4183	62	20	and	and	CCONJ
dpc-4183	62	21	11	11	NUM
dpc-4183	62	22	female/	female/	NUM
dpc-4183	62	23	25	25	NUM
dpc-4183	62	24	male	male	NOUN
dpc-4183	62	25	,	,	PUNCT
dpc-4183	62	26	respectively	respectively	ADV
dpc-4183	62	27	)	)	PUNCT
dpc-4183	62	28	of	of	ADP
dpc-4183	62	29	vitiligo	vitiligo	ADJ
dpc-4183	62	30	group	group	NOUN
dpc-4183	62	31	and	and	CCONJ
dpc-4183	62	32	control	control	NOUN
dpc-4183	62	33	group	group	NOUN
dpc-4183	62	34	were	be	AUX
dpc-4183	62	35	similar	similar	ADJ
dpc-4183	62	36	.	.	PUNCT
dpc-4183	63	1	the	the	DET
dpc-4183	63	2	most	most	ADV
dpc-4183	63	3	common	common	ADJ
dpc-4183	63	4	type	type	NOUN
dpc-4183	63	5	of	of	ADP
dpc-4183	63	6	vitiligo	vitiligo	NOUN
dpc-4183	63	7	was	be	AUX
dpc-4183	63	8	the	the	DET
dpc-4183	63	9	generalized	generalized	ADJ
dpc-4183	63	10	type	type	NOUN
dpc-4183	63	11	(	(	PUNCT
dpc-4183	63	12	70.5	70.5	NUM
dpc-4183	63	13	%	%	NOUN
dpc-4183	63	14	)	)	PUNCT
dpc-4183	63	15	,	,	PUNCT
dpc-4183	63	16	followed	follow	VERB
dpc-4183	63	17	by	by	ADP
dpc-4183	63	18	focal	focal	ADJ
dpc-4183	63	19	vitiligo	vitiligo	NOUN
dpc-4183	63	20	(	(	PUNCT
dpc-4183	63	21	25	25	NUM
dpc-4183	63	22	%	%	NOUN
dpc-4183	63	23	)	)	PUNCT
dpc-4183	63	24	and	and	CCONJ
dpc-4183	63	25	acrofacial	acrofacial	ADJ
dpc-4183	63	26	vitiligo	vitiligo	NOUN
dpc-4183	63	27	(	(	PUNCT
dpc-4183	63	28	4.5	4.5	NUM
dpc-4183	63	29	%	%	NOUN
dpc-4183	63	30	)	)	PUNCT
dpc-4183	63	31	(	(	PUNCT
dpc-4183	63	32	table	table	NOUN
dpc-4183	63	33	1	1	NUM
dpc-4183	63	34	)	)	PUNCT
dpc-4183	63	35	.	.	PUNCT
dpc-4183	64	1	the	the	DET
dpc-4183	64	2	mean	mean	ADJ
dpc-4183	64	3	disease	disease	NOUN
dpc-4183	64	4	duration	duration	NOUN
dpc-4183	64	5	was	be	AUX
dpc-4183	64	6	4.99±5.39	4.99±5.39	NOUN
dpc-4183	64	7	years	year	NOUN
dpc-4183	64	8	and	and	CCONJ
dpc-4183	64	9	ranged	range	VERB
dpc-4183	64	10	between	between	ADP
dpc-4183	64	11	0.20	0.20	NUM
dpc-4183	64	12	and	and	CCONJ
dpc-4183	64	13	26.0	26.0	NUM
dpc-4183	64	14	years	year	NOUN
dpc-4183	64	15	.	.	PUNCT
dpc-4183	65	1	the	the	DET
dpc-4183	65	2	mean	mean	ADJ
dpc-4183	65	3	±sd	±sd	NOUN
dpc-4183	65	4	values	value	NOUN
dpc-4183	65	5	for	for	ADP
dpc-4183	65	6	vasi	vasi	PROPN
dpc-4183	65	7	and	and	CCONJ
dpc-4183	65	8	vida	vida	PROPN
dpc-4183	65	9	scores	score	NOUN
dpc-4183	65	10	were	be	AUX
dpc-4183	65	11	3.04±5.66	3.04±5.66	NUM
dpc-4183	65	12	and	and	CCONJ
dpc-4183	65	13	1.59±1.70	1.59±1.70	NUM
dpc-4183	65	14	,	,	PUNCT
dpc-4183	65	15	respectively	respectively	ADV
dpc-4183	65	16	.	.	PUNCT
dpc-4183	66	1	there	there	PRON
dpc-4183	66	2	was	be	VERB
dpc-4183	66	3	a	a	DET
dpc-4183	66	4	moderate	moderate	ADJ
dpc-4183	66	5	negative	negative	ADJ
dpc-4183	66	6	correlation	correlation	NOUN
dpc-4183	66	7	between	between	ADP
dpc-4183	66	8	vasi	vasi	PROPN
dpc-4183	66	9	score	score	NOUN
dpc-4183	66	10	and	and	CCONJ
dpc-4183	66	11	disease	disease	NOUN
dpc-4183	66	12	onset	onset	VERB
dpc-4183	66	13	age	age	NOUN
dpc-4183	66	14	(	(	PUNCT
dpc-4183	66	15	r	r	NOUN
dpc-4183	66	16	=	=	SYM
dpc-4183	66	17	-0.414	-0.414	PROPN
dpc-4183	66	18	,	,	PUNCT
dpc-4183	66	19	p	p	NOUN
dpc-4183	66	20	=	=	NOUN
dpc-4183	66	21	0.05	0.05	NUM
dpc-4183	66	22	)	)	PUNCT
dpc-4183	66	23	,	,	PUNCT
dpc-4183	66	24	and	and	CCONJ
dpc-4183	66	25	a	a	DET
dpc-4183	66	26	moderate	moderate	ADJ
dpc-4183	66	27	positive	positive	ADJ
dpc-4183	66	28	correlation	correlation	NOUN
dpc-4183	66	29	between	between	ADP
dpc-4183	66	30	vasi	vasi	PROPN
dpc-4183	66	31	score	score	NOUN
dpc-4183	66	32	and	and	CCONJ
dpc-4183	66	33	disease	disease	NOUN
dpc-4183	66	34	duration	duration	NOUN
dpc-4183	66	35	(	(	PUNCT
dpc-4183	66	36	r	r	NOUN
dpc-4183	66	37	=	=	NOUN
dpc-4183	66	38	0.496	0.496	NUM
dpc-4183	66	39	,	,	PUNCT
dpc-4183	66	40	p	p	X
dpc-4183	66	41	=	=	NOUN
dpc-4183	66	42	0.01	0.01	NUM
dpc-4183	66	43	)	)	PUNCT
dpc-4183	66	44	.	.	PUNCT
dpc-4183	67	1	the	the	DET
dpc-4183	67	2	average	average	ADJ
dpc-4183	67	3	serum	serum	NOUN
dpc-4183	67	4	levels	level	NOUN
dpc-4183	67	5	of	of	ADP
dpc-4183	67	6	calprotectin	calprotectin	NOUN
dpc-4183	67	7	in	in	ADP
dpc-4183	67	8	vitiligo	vitiligo	ADJ
dpc-4183	67	9	patients	patient	NOUN
dpc-4183	67	10	and	and	CCONJ
dpc-4183	67	11	controls	control	NOUN
dpc-4183	67	12	were	be	AUX
dpc-4183	67	13	409.11±217.22	409.11±217.22	NUM
dpc-4183	67	14	and	and	CCONJ
dpc-4183	67	15	301.30±229.89	301.30±229.89	NUM
dpc-4183	67	16	,	,	PUNCT
dpc-4183	67	17	respectively	respectively	ADV
dpc-4183	67	18	.	.	PUNCT
dpc-4183	68	1	there	there	PRON
dpc-4183	68	2	was	be	VERB
dpc-4183	68	3	a	a	DET
dpc-4183	68	4	significant	significant	ADJ
dpc-4183	68	5	difference	difference	NOUN
dpc-4183	68	6	between	between	ADP
dpc-4183	68	7	the	the	DET
dpc-4183	68	8	serum	serum	NOUN
dpc-4183	68	9	calprotectin	calprotectin	NOUN
dpc-4183	68	10	levels	level	NOUN
dpc-4183	68	11	in	in	ADP
dpc-4183	68	12	patients	patient	NOUN
dpc-4183	68	13	with	with	ADP
dpc-4183	68	14	vitiligo	vitiligo	NOUN
dpc-4183	68	15	compared	compare	VERB
dpc-4183	68	16	to	to	ADP
dpc-4183	68	17	healthy	healthy	ADJ
dpc-4183	68	18	individuals	individual	NOUN
dpc-4183	68	19	(	(	PUNCT
dpc-4183	68	20	p	p	X
dpc-4183	68	21	=	=	NOUN
dpc-4183	68	22	0.016	0.016	NUM
dpc-4183	68	23	)	)	PUNCT
dpc-4183	68	24	(	(	PUNCT
dpc-4183	68	25	table	table	NOUN
dpc-4183	68	26	2	2	NUM
dpc-4183	68	27	)	)	PUNCT
dpc-4183	68	28	.	.	PUNCT
dpc-4183	69	1	fourteen	fourteen	NUM
dpc-4183	69	2	(	(	PUNCT
dpc-4183	69	3	31.8	31.8	NUM
dpc-4183	69	4	%	%	NOUN
dpc-4183	69	5	)	)	PUNCT
dpc-4183	69	6	of	of	ADP
dpc-4183	69	7	the	the	DET
dpc-4183	69	8	patients	patient	NOUN
dpc-4183	69	9	had	have	VERB
dpc-4183	69	10	at	at	ADV
dpc-4183	69	11	least	least	ADV
dpc-4183	69	12	one	one	NUM
dpc-4183	69	13	family	family	NOUN
dpc-4183	69	14	member	member	NOUN
dpc-4183	69	15	with	with	ADP
dpc-4183	69	16	vitiligo	vitiligo	PROPN
dpc-4183	69	17	.	.	PUNCT
dpc-4183	70	1	leukotrichia	leukotrichia	PROPN
dpc-4183	70	2	was	be	AUX
dpc-4183	70	3	found	find	VERB
dpc-4183	70	4	in	in	ADP
dpc-4183	70	5	22	22	NUM
dpc-4183	70	6	(	(	PUNCT
dpc-4183	70	7	50	50	NUM
dpc-4183	70	8	%	%	NOUN
dpc-4183	70	9	)	)	PUNCT
dpc-4183	70	10	original	original	ADJ
dpc-4183	70	11	article	article	NOUN
dpc-4183	70	12	|	|	ADV
dpc-4183	70	13	dermatol	dermatol	ADJ
dpc-4183	70	14	pract	pract	NOUN
dpc-4183	70	15	concept	concept	NOUN
dpc-4183	70	16	.	.	PUNCT
dpc-4183	71	1	2024;14(3):e2024184	2024;14(3):e2024184	NUM
dpc-4183	71	2	3	3	NUM
dpc-4183	71	3	of	of	ADP
dpc-4183	71	4	the	the	DET
dpc-4183	71	5	patients	patient	NOUN
dpc-4183	71	6	.	.	PUNCT
dpc-4183	72	1	there	there	PRON
dpc-4183	72	2	was	be	VERB
dpc-4183	72	3	no	no	DET
dpc-4183	72	4	association	association	NOUN
dpc-4183	72	5	between	between	ADP
dpc-4183	72	6	the	the	DET
dpc-4183	72	7	calprotectin	calprotectin	NOUN
dpc-4183	72	8	level	level	NOUN
dpc-4183	72	9	and	and	CCONJ
dpc-4183	72	10	family	family	NOUN
dpc-4183	72	11	history	history	NOUN
dpc-4183	72	12	,	,	PUNCT
dpc-4183	72	13	leukotrichia	leukotrichia	NOUN
dpc-4183	72	14	,	,	PUNCT
dpc-4183	72	15	smoking	smoking	NOUN
dpc-4183	72	16	,	,	PUNCT
dpc-4183	72	17	body	body	NOUN
dpc-4183	72	18	mass	mass	PROPN
dpc-4183	72	19	index	index	NOUN
dpc-4183	72	20	,	,	PUNCT
dpc-4183	72	21	disease	disease	NOUN
dpc-4183	72	22	subtype	subtype	NOUN
dpc-4183	72	23	,	,	PUNCT
dpc-4183	72	24	or	or	CCONJ
dpc-4183	72	25	skin	skin	NOUN
dpc-4183	72	26	phototype	phototype	NOUN
dpc-4183	72	27	.	.	PUNCT
dpc-4183	73	1	seventeen	seventeen	NUM
dpc-4183	73	2	(	(	PUNCT
dpc-4183	73	3	38.6	38.6	NUM
dpc-4183	73	4	%	%	NOUN
dpc-4183	73	5	)	)	PUNCT
dpc-4183	73	6	patients	patient	NOUN
dpc-4183	73	7	had	have	AUX
dpc-4183	73	8	received	receive	VERB
dpc-4183	73	9	topical	topical	ADJ
dpc-4183	73	10	/	/	SYM
dpc-4183	73	11	systemic	systemic	ADJ
dpc-4183	73	12	treatment	treatment	NOUN
dpc-4183	73	13	in	in	ADP
dpc-4183	73	14	the	the	DET
dpc-4183	73	15	previous	previous	ADJ
dpc-4183	73	16	six	six	NUM
dpc-4183	73	17	months	month	NOUN
dpc-4183	73	18	,	,	PUNCT
dpc-4183	73	19	five	five	NUM
dpc-4183	73	20	(	(	PUNCT
dpc-4183	73	21	29.4	29.4	NUM
dpc-4183	73	22	%	%	NOUN
dpc-4183	73	23	)	)	PUNCT
dpc-4183	73	24	of	of	ADP
dpc-4183	73	25	the	the	DET
dpc-4183	73	26	patients	patient	NOUN
dpc-4183	73	27	used	use	VERB
dpc-4183	73	28	topical	topical	ADJ
dpc-4183	73	29	corticosteroid	corticosteroid	NOUN
dpc-4183	73	30	,	,	PUNCT
dpc-4183	73	31	and	and	CCONJ
dpc-4183	73	32	15	15	NUM
dpc-4183	73	33	(	(	PUNCT
dpc-4183	73	34	70.6	70.6	NUM
dpc-4183	73	35	%	%	NOUN
dpc-4183	73	36	)	)	PUNCT
dpc-4183	73	37	used	use	VERB
dpc-4183	73	38	topical	topical	ADJ
dpc-4183	73	39	calcineurin	calcineurin	NOUN
dpc-4183	73	40	inhibitor	inhibitor	NOUN
dpc-4183	73	41	.	.	PUNCT
dpc-4183	74	1	twenty	twenty	NUM
dpc-4183	74	2	-	-	PUNCT
dpc-4183	74	3	seven	seven	NUM
dpc-4183	74	4	(	(	PUNCT
dpc-4183	74	5	61.4	61.4	NUM
dpc-4183	74	6	%	%	NOUN
dpc-4183	74	7	)	)	PUNCT
dpc-4183	75	1	patients	patient	NOUN
dpc-4183	75	2	had	have	AUX
dpc-4183	75	3	not	not	PART
dpc-4183	75	4	received	receive	VERB
dpc-4183	75	5	any	any	DET
dpc-4183	75	6	treatment	treatment	NOUN
dpc-4183	75	7	in	in	ADP
dpc-4183	75	8	the	the	DET
dpc-4183	75	9	previous	previous	ADJ
dpc-4183	75	10	six	six	NUM
dpc-4183	75	11	months	month	NOUN
dpc-4183	75	12	.	.	PUNCT
dpc-4183	76	1	serum	serum	NOUN
dpc-4183	76	2	calprotectin	calprotectin	NOUN
dpc-4183	76	3	levels	level	NOUN
dpc-4183	76	4	were	be	AUX
dpc-4183	76	5	found	find	VERB
dpc-4183	76	6	to	to	PART
dpc-4183	76	7	be	be	AUX
dpc-4183	76	8	significantly	significantly	ADV
dpc-4183	76	9	higher	high	ADJ
dpc-4183	76	10	in	in	ADP
dpc-4183	76	11	people	people	NOUN
dpc-4183	76	12	who	who	PRON
dpc-4183	76	13	had	have	AUX
dpc-4183	76	14	received	receive	VERB
dpc-4183	76	15	treatment	treatment	NOUN
dpc-4183	76	16	in	in	ADP
dpc-4183	76	17	the	the	DET
dpc-4183	76	18	previous	previous	ADJ
dpc-4183	76	19	six	six	NUM
dpc-4183	76	20	months	month	NOUN
dpc-4183	76	21	(	(	PUNCT
dpc-4183	76	22	p	p	NOUN
dpc-4183	76	23	=	=	NOUN
dpc-4183	76	24	0.013	0.013	NUM
dpc-4183	76	25	)	)	PUNCT
dpc-4183	76	26	(	(	PUNCT
dpc-4183	76	27	table	table	NOUN
dpc-4183	76	28	1	1	NUM
dpc-4183	76	29	)	)	PUNCT
dpc-4183	76	30	.	.	PUNCT
dpc-4183	77	1	no	no	DET
dpc-4183	77	2	correlation	correlation	NOUN
dpc-4183	77	3	was	be	AUX
dpc-4183	77	4	found	find	VERB
dpc-4183	77	5	between	between	ADP
dpc-4183	77	6	serum	serum	NOUN
dpc-4183	77	7	calprotectin	calprotectin	NOUN
dpc-4183	77	8	level	level	NOUN
dpc-4183	77	9	and	and	CCONJ
dpc-4183	77	10	age	age	NOUN
dpc-4183	77	11	,	,	PUNCT
dpc-4183	77	12	age	age	NOUN
dpc-4183	77	13	at	at	ADP
dpc-4183	77	14	disease	disease	NOUN
dpc-4183	77	15	onset	onset	VERB
dpc-4183	77	16	,	,	PUNCT
dpc-4183	77	17	disease	disease	NOUN
dpc-4183	77	18	duration	duration	NOUN
dpc-4183	77	19	,	,	PUNCT
dpc-4183	77	20	vasi	vasi	PROPN
dpc-4183	77	21	,	,	PUNCT
dpc-4183	77	22	or	or	CCONJ
dpc-4183	77	23	vida	vida	PROPN
dpc-4183	77	24	scores	score	NOUN
dpc-4183	77	25	in	in	ADP
dpc-4183	77	26	patients	patient	NOUN
dpc-4183	77	27	(	(	PUNCT
dpc-4183	77	28	table	table	NOUN
dpc-4183	77	29	3	3	NUM
dpc-4183	77	30	)	)	PUNCT
dpc-4183	77	31	.	.	PUNCT
dpc-4183	78	1	using	use	VERB
dpc-4183	78	2	the	the	DET
dpc-4183	78	3	distribution	distribution	NOUN
dpc-4183	78	4	of	of	ADP
dpc-4183	78	5	serum	serum	NOUN
dpc-4183	78	6	calprotectin	calprotectin	NOUN
dpc-4183	78	7	values	value	NOUN
dpc-4183	78	8	in	in	ADP
dpc-4183	78	9	the	the	DET
dpc-4183	78	10	patient	patient	ADJ
dpc-4183	78	11	and	and	CCONJ
dpc-4183	78	12	control	control	NOUN
dpc-4183	78	13	groups	group	NOUN
dpc-4183	78	14	,	,	PUNCT
dpc-4183	78	15	roc	roc	NOUN
dpc-4183	78	16	analysis	analysis	NOUN
dpc-4183	78	17	was	be	AUX
dpc-4183	78	18	performed	perform	VERB
dpc-4183	78	19	to	to	PART
dpc-4183	78	20	calculate	calculate	VERB
dpc-4183	78	21	a	a	DET
dpc-4183	78	22	cutoff	cutoff	NOUN
dpc-4183	78	23	value	value	NOUN
dpc-4183	78	24	.	.	PUNCT
dpc-4183	79	1	in	in	ADP
dpc-4183	79	2	this	this	DET
dpc-4183	79	3	analysis	analysis	NOUN
dpc-4183	79	4	,	,	PUNCT
dpc-4183	79	5	sensitivity	sensitivity	NOUN
dpc-4183	79	6	,	,	PUNCT
dpc-4183	79	7	specificity	specificity	NOUN
dpc-4183	79	8	,	,	PUNCT
dpc-4183	79	9	and	and	CCONJ
dpc-4183	79	10	area	area	NOUN
dpc-4183	79	11	under	under	ADP
dpc-4183	79	12	the	the	DET
dpc-4183	79	13	curve	curve	NOUN
dpc-4183	79	14	(	(	PUNCT
dpc-4183	79	15	auc	auc	NOUN
dpc-4183	79	16	)	)	PUNCT
dpc-4183	79	17	were	be	AUX
dpc-4183	79	18	calculated	calculate	VERB
dpc-4183	79	19	,	,	PUNCT
dpc-4183	79	20	and	and	CCONJ
dpc-4183	79	21	the	the	DET
dpc-4183	79	22	test	test	NOUN
dpc-4183	79	23	statistic	statistic	NOUN
dpc-4183	79	24	was	be	AUX
dpc-4183	79	25	significant	significant	ADJ
dpc-4183	79	26	(	(	PUNCT
dpc-4183	79	27	p	p	X
dpc-4183	79	28	<	<	X
dpc-4183	79	29	0.001	0.001	NUM
dpc-4183	79	30	)	)	PUNCT
dpc-4183	79	31	.	.	PUNCT
dpc-4183	80	1	the	the	DET
dpc-4183	80	2	cutoff	cutoff	NOUN
dpc-4183	80	3	value	value	NOUN
dpc-4183	80	4	was	be	AUX
dpc-4183	80	5	determined	determine	VERB
dpc-4183	80	6	as	as	ADP
dpc-4183	80	7	445.64	445.64	NUM
dpc-4183	80	8	pg	pg	NOUN
dpc-4183	80	9	/	/	SYM
dpc-4183	80	10	ml	ml	NOUN
dpc-4183	80	11	with	with	ADP
dpc-4183	80	12	the	the	DET
dpc-4183	80	13	youden	youden	PROPN
dpc-4183	80	14	index	index	NOUN
dpc-4183	80	15	method	method	NOUN
dpc-4183	80	16	(	(	PUNCT
dpc-4183	80	17	table	table	NOUN
dpc-4183	80	18	4	4	NUM
dpc-4183	80	19	)	)	PUNCT
dpc-4183	80	20	.	.	PUNCT
dpc-4183	81	1	discussion	discussion	NOUN
dpc-4183	81	2	the	the	DET
dpc-4183	81	3	soluble	soluble	ADJ
dpc-4183	81	4	form	form	NOUN
dpc-4183	81	5	of	of	ADP
dpc-4183	81	6	calprotectin	calprotectin	NOUN
dpc-4183	81	7	,	,	PUNCT
dpc-4183	81	8	which	which	PRON
dpc-4183	81	9	we	we	PRON
dpc-4183	81	10	investigated	investigate	VERB
dpc-4183	81	11	in	in	ADP
dpc-4183	81	12	our	our	PRON
dpc-4183	81	13	study	study	NOUN
dpc-4183	81	14	,	,	PUNCT
dpc-4183	81	15	can	can	AUX
dpc-4183	81	16	be	be	AUX
dpc-4183	81	17	detected	detect	VERB
dpc-4183	81	18	in	in	ADP
dpc-4183	81	19	plasma	plasma	NOUN
dpc-4183	81	20	,	,	PUNCT
dpc-4183	81	21	body	body	NOUN
dpc-4183	81	22	fluids	fluid	NOUN
dpc-4183	81	23	,	,	PUNCT
dpc-4183	81	24	and	and	CCONJ
dpc-4183	81	25	feces	fece	NOUN
dpc-4183	81	26	[	[	X
dpc-4183	81	27	7	7	NUM
dpc-4183	81	28	-	-	SYM
dpc-4183	81	29	9	9	NUM
dpc-4183	81	30	]	]	PUNCT
dpc-4183	81	31	.	.	PUNCT
dpc-4183	82	1	serum	serum	PROPN
dpc-4183	82	2	calprotectin	calprotectin	PROPN
dpc-4183	82	3	(	(	PUNCT
dpc-4183	82	4	s100a8	s100a8	PROPN
dpc-4183	82	5	/	/	SYM
dpc-4183	82	6	s100a9	s100a9	PROPN
dpc-4183	82	7	protein	protein	NOUN
dpc-4183	82	8	)	)	PUNCT
dpc-4183	82	9	has	have	AUX
dpc-4183	82	10	been	be	AUX
dpc-4183	82	11	investigated	investigate	VERB
dpc-4183	82	12	in	in	ADP
dpc-4183	82	13	inflammatory	inflammatory	ADJ
dpc-4183	82	14	diseases	disease	NOUN
dpc-4183	82	15	.	.	PUNCT
dpc-4183	83	1	jarlborg	jarlborg	NOUN
dpc-4183	83	2	et	et	PROPN
dpc-4183	83	3	al	al	PROPN
dpc-4183	83	4	.	.	PROPN
dpc-4183	83	5	’s	’s	PART
dpc-4183	83	6	study	study	NOUN
dpc-4183	83	7	of	of	ADP
dpc-4183	83	8	patients	patient	NOUN
dpc-4183	83	9	with	with	ADP
dpc-4183	83	10	rheumatoid	rheumatoid	NOUN
dpc-4183	83	11	arthritis	arthritis	NOUN
dpc-4183	83	12	,	,	PUNCT
dpc-4183	83	13	axial	axial	ADJ
dpc-4183	83	14	spondylarthritis	spondylarthritis	NOUN
dpc-4183	83	15	,	,	PUNCT
dpc-4183	83	16	and	and	CCONJ
dpc-4183	83	17	psoriatic	psoriatic	ADJ
dpc-4183	83	18	arthritis	arthritis	NOUN
dpc-4183	83	19	found	find	VERB
dpc-4183	83	20	that	that	SCONJ
dpc-4183	83	21	the	the	DET
dpc-4183	83	22	serum	serum	NOUN
dpc-4183	83	23	calprotectin	calprotectin	NOUN
dpc-4183	83	24	levels	level	NOUN
dpc-4183	83	25	were	be	AUX
dpc-4183	83	26	higher	high	ADJ
dpc-4183	83	27	in	in	ADP
dpc-4183	83	28	all	all	DET
dpc-4183	83	29	three	three	NUM
dpc-4183	83	30	groups	group	NOUN
dpc-4183	83	31	of	of	ADP
dpc-4183	83	32	patients	patient	NOUN
dpc-4183	83	33	than	than	ADP
dpc-4183	83	34	in	in	ADP
dpc-4183	83	35	the	the	DET
dpc-4183	83	36	control	control	NOUN
dpc-4183	83	37	group	group	NOUN
dpc-4183	84	1	[	[	X
dpc-4183	84	2	9	9	NUM
dpc-4183	84	3	]	]	PUNCT
dpc-4183	84	4	.	.	PUNCT
dpc-4183	85	1	güzel	güzel	PROPN
dpc-4183	85	2	et	et	PROPN
dpc-4183	85	3	al	al	PROPN
dpc-4183	85	4	.	.	PROPN
dpc-4183	85	5	determined	determine	VERB
dpc-4183	85	6	that	that	SCONJ
dpc-4183	85	7	serum	serum	NOUN
dpc-4183	85	8	calprotectin	calprotectin	NOUN
dpc-4183	85	9	levels	level	NOUN
dpc-4183	85	10	were	be	AUX
dpc-4183	85	11	higher	high	ADJ
dpc-4183	85	12	in	in	ADP
dpc-4183	85	13	patients	patient	NOUN
dpc-4183	85	14	with	with	ADP
dpc-4183	85	15	psoriasis	psoriasis	NOUN
dpc-4183	85	16	vulgaris	vulgaris	NOUN
dpc-4183	85	17	compared	compare	VERB
dpc-4183	85	18	to	to	ADP
dpc-4183	85	19	the	the	DET
dpc-4183	85	20	control	control	NOUN
dpc-4183	85	21	group	group	NOUN
dpc-4183	85	22	and	and	CCONJ
dpc-4183	85	23	that	that	SCONJ
dpc-4183	85	24	they	they	PRON
dpc-4183	85	25	increased	increase	VERB
dpc-4183	85	26	with	with	ADP
dpc-4183	85	27	disease	disease	NOUN
dpc-4183	85	28	severity	severity	NOUN
dpc-4183	85	29	.	.	PUNCT
dpc-4183	86	1	the	the	DET
dpc-4183	86	2	study	study	NOUN
dpc-4183	86	3	concluded	conclude	VERB
dpc-4183	86	4	that	that	SCONJ
dpc-4183	86	5	calprotectin	calprotectin	NOUN
dpc-4183	86	6	,	,	PUNCT
dpc-4183	86	7	table	table	NOUN
dpc-4183	86	8	1	1	NUM
dpc-4183	86	9	.	.	PUNCT
dpc-4183	87	1	the	the	DET
dpc-4183	87	2	relationship	relationship	NOUN
dpc-4183	87	3	between	between	ADP
dpc-4183	87	4	patients	patient	NOUN
dpc-4183	87	5	’	’	PART
dpc-4183	87	6	variables	variable	NOUN
dpc-4183	87	7	and	and	CCONJ
dpc-4183	87	8	calprotectin	calprotectin	NOUN
dpc-4183	87	9	level	level	NOUN
dpc-4183	87	10	n	n	CCONJ
dpc-4183	87	11	(	(	PUNCT
dpc-4183	87	12	%	%	INTJ
dpc-4183	87	13	)	)	PUNCT
dpc-4183	87	14	calprotectin	calprotectin	NOUN
dpc-4183	87	15	level	level	NOUN
dpc-4183	87	16	p	p	NOUN
dpc-4183	87	17	smoking	smoking	NOUN
dpc-4183	87	18	no	no	DET
dpc-4183	87	19	25	25	NUM
dpc-4183	87	20	(	(	PUNCT
dpc-4183	87	21	56.8	56.8	NUM
dpc-4183	87	22	%	%	NOUN
dpc-4183	87	23	)	)	PUNCT
dpc-4183	88	1	424.19±224.55	424.19±224.55	NUM
dpc-4183	88	2	0.749	0.749	NUM
dpc-4183	89	1	yes	yes	NOUN
dpc-4183	89	2	19	19	NUM
dpc-4183	89	3	(	(	PUNCT
dpc-4183	89	4	43.2	43.2	NUM
dpc-4183	89	5	%	%	NOUN
dpc-4183	89	6	)	)	PUNCT
dpc-4183	90	1	363.78±217.76	363.78±217.76	NUM
dpc-4183	90	2	family	family	NOUN
dpc-4183	90	3	history	history	NOUN
dpc-4183	90	4	no	no	DET
dpc-4183	90	5	30	30	NUM
dpc-4183	90	6	(	(	PUNCT
dpc-4183	90	7	68.2	68.2	NUM
dpc-4183	90	8	%	%	NOUN
dpc-4183	90	9	)	)	PUNCT
dpc-4183	90	10	430.26±217.38	430.26±217.38	NUM
dpc-4183	90	11	0.320	0.320	NUM
dpc-4183	90	12	yes	yes	NUM
dpc-4183	90	13	14	14	NUM
dpc-4183	90	14	(	(	PUNCT
dpc-4183	90	15	31.8	31.8	NUM
dpc-4183	90	16	%	%	NOUN
dpc-4183	90	17	)	)	PUNCT
dpc-4183	91	1	363.78±217.76	363.78±217.76	NUM
dpc-4183	91	2	leukotrichia	leukotrichia	NOUN
dpc-4183	91	3	no	no	DET
dpc-4183	91	4	22	22	NUM
dpc-4183	91	5	(	(	PUNCT
dpc-4183	91	6	50	50	NUM
dpc-4183	91	7	%	%	NOUN
dpc-4183	91	8	)	)	PUNCT
dpc-4183	91	9	473.45±204.97	473.45±204.97	NOUN
dpc-4183	91	10	0.073	0.073	NUM
dpc-4183	92	1	yes	yes	NUM
dpc-4183	92	2	22	22	NUM
dpc-4183	92	3	(	(	PUNCT
dpc-4183	92	4	50	50	NUM
dpc-4183	92	5	%	%	NOUN
dpc-4183	92	6	)	)	PUNCT
dpc-4183	92	7	344.77±214.32	344.77±214.32	NUM
dpc-4183	92	8	bmi	bmi	NOUN
dpc-4183	92	9	(	(	PUNCT
dpc-4183	92	10	body	body	NOUN
dpc-4183	92	11	mass	mass	PROPN
dpc-4183	92	12	index	index	NOUN
dpc-4183	92	13	)	)	PUNCT
dpc-4183	92	14	normal	normal	ADJ
dpc-4183	92	15	20	20	NUM
dpc-4183	92	16	(	(	PUNCT
dpc-4183	92	17	45.5	45.5	NUM
dpc-4183	92	18	%	%	NOUN
dpc-4183	92	19	)	)	PUNCT
dpc-4183	92	20	441.05±203.01	441.05±203.01	NUM
dpc-4183	92	21	0.423	0.423	NUM
dpc-4183	92	22	overweight	overweight	NOUN
dpc-4183	92	23	24	24	NUM
dpc-4183	92	24	(	(	PUNCT
dpc-4183	92	25	54.5	54.5	NUM
dpc-4183	92	26	%	%	NOUN
dpc-4183	92	27	)	)	PUNCT
dpc-4183	93	1	382.49±229.23	382.49±229.23	NUM
dpc-4183	93	2	vitiligo	vitiligo	ADJ
dpc-4183	93	3	subtype	subtype	NOUN
dpc-4183	93	4	generalized	generalize	VERB
dpc-4183	93	5	31	31	NUM
dpc-4183	93	6	(	(	PUNCT
dpc-4183	93	7	70.5	70.5	NUM
dpc-4183	93	8	%	%	NOUN
dpc-4183	93	9	)	)	PUNCT
dpc-4183	94	1	423.42±213.60	423.42±213.60	NUM
dpc-4183	94	2	0.653	0.653	NUM
dpc-4183	94	3	focal	focal	ADJ
dpc-4183	94	4	11	11	NUM
dpc-4183	94	5	(	(	PUNCT
dpc-4183	94	6	25	25	NUM
dpc-4183	94	7	%	%	NOUN
dpc-4183	94	8	)	)	PUNCT
dpc-4183	95	1	356.54±243.51	356.54±243.51	PROPN
dpc-4183	95	2	akrofacial	akrofacial	ADJ
dpc-4183	95	3	2	2	NUM
dpc-4183	95	4	(	(	PUNCT
dpc-4183	95	5	4.5	4.5	NUM
dpc-4183	95	6	%	%	NOUN
dpc-4183	95	7	)	)	PUNCT
dpc-4183	96	1	476.46±146.46	476.46±146.46	NUM
dpc-4183	96	2	skin	skin	NOUN
dpc-4183	96	3	phototype	phototype	NOUN
dpc-4183	96	4	2	2	NUM
dpc-4183	96	5	8	8	NUM
dpc-4183	96	6	(	(	PUNCT
dpc-4183	96	7	18.2	18.2	NUM
dpc-4183	96	8	%	%	NOUN
dpc-4183	96	9	)	)	PUNCT
dpc-4183	96	10	336.8±192.02	336.8±192.02	NUM
dpc-4183	96	11	0.671	0.671	NUM
dpc-4183	96	12	3	3	NUM
dpc-4183	96	13	17	17	NUM
dpc-4183	96	14	(	(	PUNCT
dpc-4183	96	15	38	38	NUM
dpc-4183	96	16	.	.	NOUN
dpc-4183	96	17	6	6	NUM
dpc-4183	96	18	%	%	NOUN
dpc-4183	96	19	)	)	PUNCT
dpc-4183	96	20	405.6±209.41	405.6±209.41	NOUN
dpc-4183	96	21	4	4	NUM
dpc-4183	96	22	18	18	NUM
dpc-4183	96	23	(	(	PUNCT
dpc-4183	96	24	40.9	40.9	NUM
dpc-4183	96	25	%	%	NOUN
dpc-4183	96	26	)	)	PUNCT
dpc-4183	97	1	437.24±242.01	437.24±242.01	NUM
dpc-4183	97	2	6	6	NUM
dpc-4183	97	3	1	1	NUM
dpc-4183	97	4	(	(	PUNCT
dpc-4183	97	5	2.3	2.3	NUM
dpc-4183	97	6	%	%	NOUN
dpc-4183	97	7	)	)	PUNCT
dpc-4183	97	8	540.86	540.86	NUM
dpc-4183	97	9	treatment	treatment	NOUN
dpc-4183	97	10	(	(	PUNCT
dpc-4183	97	11	last	last	ADJ
dpc-4183	97	12	6	6	NUM
dpc-4183	97	13	months	month	NOUN
dpc-4183	97	14	)	)	PUNCT
dpc-4183	97	15	no	no	DET
dpc-4183	97	16	27	27	NUM
dpc-4183	97	17	(	(	PUNCT
dpc-4183	97	18	61.4	61.4	NUM
dpc-4183	97	19	%	%	NOUN
dpc-4183	97	20	)	)	PUNCT
dpc-4183	97	21	341.66±184.70	341.66±184.70	NUM
dpc-4183	97	22	0.013	0.013	NUM
dpc-4183	97	23	*	*	PUNCT
dpc-4183	97	24	yes	yes	INTJ
dpc-4183	97	25	17	17	NUM
dpc-4183	97	26	(	(	PUNCT
dpc-4183	97	27	38.6	38.6	NUM
dpc-4183	97	28	%	%	NOUN
dpc-4183	97	29	)	)	PUNCT
dpc-4183	98	1	516.24±226.94	516.24±226.94	NUM
dpc-4183	98	2	table	table	NOUN
dpc-4183	98	3	2	2	NUM
dpc-4183	98	4	.	.	PUNCT
dpc-4183	98	5	comparison	comparison	NOUN
dpc-4183	98	6	of	of	ADP
dpc-4183	98	7	serum	serum	NOUN
dpc-4183	98	8	calprotectin	calprotectin	NOUN
dpc-4183	98	9	levels	level	NOUN
dpc-4183	98	10	of	of	ADP
dpc-4183	98	11	the	the	DET
dpc-4183	98	12	patient	patient	ADJ
dpc-4183	98	13	and	and	CCONJ
dpc-4183	98	14	control	control	NOUN
dpc-4183	98	15	groups	group	NOUN
dpc-4183	98	16	mean	mean	VERB
dpc-4183	98	17	±	±	NOUN
dpc-4183	98	18	sd	sd	ADP
dpc-4183	98	19	median	median	PROPN
dpc-4183	98	20	(	(	PUNCT
dpc-4183	98	21	min.-max	min.-max	X
dpc-4183	98	22	.	.	PUNCT
dpc-4183	98	23	)	)	PUNCT
dpc-4183	99	1	p	p	NOUN
dpc-4183	99	2	value	value	NOUN
dpc-4183	99	3	patients	patient	NOUN
dpc-4183	99	4	409.11±217.22	409.11±217.22	NUM
dpc-4183	99	5	454.08	454.08	NUM
dpc-4183	99	6	pg	pg	NOUN
dpc-4183	99	7	/	/	SYM
dpc-4183	99	8	ml	ml	PROPN
dpc-4183	99	9	(	(	PUNCT
dpc-4183	99	10	41.19	41.19	NUM
dpc-4183	99	11	-	-	SYM
dpc-4183	99	12	873.41	873.41	NUM
dpc-4183	99	13	)	)	PUNCT
dpc-4183	99	14	0.016	0.016	NUM
dpc-4183	99	15	*	*	PUNCT
dpc-4183	99	16	controls	control	VERB
dpc-4183	99	17	301.30±229.89	301.30±229.89	NUM
dpc-4183	99	18	223.17	223.17	NUM
dpc-4183	99	19	pg	pg	NOUN
dpc-4183	99	20	/	/	SYM
dpc-4183	99	21	ml	ml	PROPN
dpc-4183	99	22	(	(	PUNCT
dpc-4183	99	23	44.88	44.88	NUM
dpc-4183	99	24	-	-	SYM
dpc-4183	99	25	1044.43	1044.43	NUM
dpc-4183	99	26	)	)	PUNCT
dpc-4183	99	27	*	*	PUNCT
dpc-4183	100	1	p	p	X
dpc-4183	100	2	<	<	X
dpc-4183	100	3	0.05	0.05	NUM
dpc-4183	100	4	table	table	NOUN
dpc-4183	100	5	3	3	NUM
dpc-4183	100	6	.	.	X
dpc-4183	100	7	correlation	correlation	NOUN
dpc-4183	100	8	between	between	ADP
dpc-4183	100	9	serum	serum	NOUN
dpc-4183	100	10	calprotectin	calprotectin	NOUN
dpc-4183	100	11	levels	level	NOUN
dpc-4183	100	12	and	and	CCONJ
dpc-4183	100	13	age	age	NOUN
dpc-4183	100	14	,	,	PUNCT
dpc-4183	100	15	disease	disease	NOUN
dpc-4183	100	16	onset	onset	VERB
dpc-4183	100	17	age	age	NOUN
dpc-4183	100	18	,	,	PUNCT
dpc-4183	100	19	disease	disease	NOUN
dpc-4183	100	20	duration	duration	NOUN
dpc-4183	100	21	,	,	PUNCT
dpc-4183	100	22	vasi	vasi	PROPN
dpc-4183	100	23	,	,	PUNCT
dpc-4183	100	24	and	and	CCONJ
dpc-4183	100	25	vida	vida	PROPN
dpc-4183	100	26	scores	score	NOUN
dpc-4183	100	27	in	in	ADP
dpc-4183	100	28	 	 	SPACE
dpc-4183	100	29	patients	patient	NOUN
dpc-4183	100	30	r	r	X
dpc-4183	100	31	p	p	X
dpc-4183	100	32	*	*	X
dpc-4183	100	33	age	age	NOUN
dpc-4183	100	34	0.065	0.065	NUM
dpc-4183	100	35	0.677	0.677	NUM
dpc-4183	100	36	disease	disease	NOUN
dpc-4183	100	37	onset	onset	VERB
dpc-4183	100	38	age	age	NOUN
dpc-4183	100	39	0.117	0.117	NUM
dpc-4183	100	40	0.448	0.448	NUM
dpc-4183	100	41	disease	disease	NOUN
dpc-4183	100	42	duration	duration	NOUN
dpc-4183	100	43	−0.234	−0.234	VERB
dpc-4183	100	44	0.127	0.127	NUM
dpc-4183	100	45	vasi	vasi	PROPN
dpc-4183	100	46	0.004	0.004	NUM
dpc-4183	100	47	0.977	0.977	NUM
dpc-4183	100	48	vida	vida	NOUN
dpc-4183	100	49	−0.161	−0.161	VERB
dpc-4183	100	50	0.298	0.298	NUM
dpc-4183	100	51	*	*	PUNCT
dpc-4183	100	52	p	p	X
dpc-4183	100	53	<	<	X
dpc-4183	100	54	0.05	0.05	NUM
dpc-4183	100	55	4	4	NUM
dpc-4183	100	56	original	original	ADJ
dpc-4183	100	57	article	article	NOUN
dpc-4183	100	58	|	|	ADV
dpc-4183	100	59	dermatol	dermatol	ADJ
dpc-4183	100	60	pract	pract	NOUN
dpc-4183	100	61	concept	concept	NOUN
dpc-4183	100	62	.	.	PUNCT
dpc-4183	101	1	2024;14(3):e2024184	2024;14(3):e2024184	NUM
dpc-4183	101	2	months	month	NOUN
dpc-4183	101	3	(	(	PUNCT
dpc-4183	101	4	p	p	X
dpc-4183	101	5	=	=	NOUN
dpc-4183	101	6	0.013	0.013	NUM
dpc-4183	101	7	)	)	PUNCT
dpc-4183	101	8	.	.	PUNCT
dpc-4183	102	1	as	as	SCONJ
dpc-4183	102	2	vitiligo	vitiligo	NOUN
dpc-4183	102	3	is	be	AUX
dpc-4183	102	4	a	a	DET
dpc-4183	102	5	chronic	chronic	ADJ
dpc-4183	102	6	and	and	CCONJ
dpc-4183	102	7	typically	typically	ADV
dpc-4183	102	8	lifelong	lifelong	ADJ
dpc-4183	102	9	condition	condition	NOUN
dpc-4183	102	10	,	,	PUNCT
dpc-4183	102	11	patients	patient	NOUN
dpc-4183	102	12	have	have	VERB
dpc-4183	102	13	a	a	DET
dpc-4183	102	14	tendency	tendency	NOUN
dpc-4183	102	15	to	to	PART
dpc-4183	102	16	cease	cease	VERB
dpc-4183	102	17	treatment	treatment	NOUN
dpc-4183	102	18	with	with	ADP
dpc-4183	102	19	increasing	increase	VERB
dpc-4183	102	20	disease	disease	NOUN
dpc-4183	102	21	duration	duration	NOUN
dpc-4183	102	22	.	.	PUNCT
dpc-4183	103	1	calprotectin	calprotectin	NOUN
dpc-4183	103	2	levels	level	NOUN
dpc-4183	103	3	are	be	AUX
dpc-4183	103	4	expected	expect	VERB
dpc-4183	103	5	to	to	PART
dpc-4183	103	6	be	be	AUX
dpc-4183	103	7	elevated	elevate	VERB
dpc-4183	103	8	because	because	SCONJ
dpc-4183	103	9	the	the	DET
dpc-4183	103	10	patients	patient	NOUN
dpc-4183	103	11	treated	treat	VERB
dpc-4183	103	12	within	within	ADP
dpc-4183	103	13	the	the	DET
dpc-4183	103	14	last	last	ADJ
dpc-4183	103	15	six	six	NUM
dpc-4183	103	16	months	month	NOUN
dpc-4183	103	17	are	be	AUX
dpc-4183	103	18	either	either	CCONJ
dpc-4183	103	19	in	in	ADP
dpc-4183	103	20	early	early	ADJ
dpc-4183	103	21	disease	disease	NOUN
dpc-4183	103	22	or	or	CCONJ
dpc-4183	103	23	are	be	AUX
dpc-4183	103	24	sufficiently	sufficiently	ADV
dpc-4183	103	25	in	in	ADP
dpc-4183	103	26	the	the	DET
dpc-4183	103	27	active	active	ADJ
dpc-4183	103	28	period	period	NOUN
dpc-4183	103	29	of	of	ADP
dpc-4183	103	30	the	the	DET
dpc-4183	103	31	disease	disease	NOUN
dpc-4183	103	32	to	to	PART
dpc-4183	103	33	require	require	VERB
dpc-4183	103	34	medical	medical	ADJ
dpc-4183	103	35	intervention	intervention	NOUN
dpc-4183	103	36	.	.	PUNCT
dpc-4183	104	1	in	in	ADP
dpc-4183	104	2	other	other	ADJ
dpc-4183	104	3	words	word	NOUN
dpc-4183	104	4	,	,	PUNCT
dpc-4183	104	5	since	since	SCONJ
dpc-4183	104	6	calprotectin	calprotectin	NOUN
dpc-4183	104	7	also	also	ADV
dpc-4183	104	8	functions	function	NOUN
dpc-4183	104	9	as	as	ADP
dpc-4183	104	10	an	an	DET
dpc-4183	104	11	alarmin	alarmin	NOUN
dpc-4183	104	12	whose	whose	DET
dpc-4183	104	13	levels	level	NOUN
dpc-4183	104	14	are	be	AUX
dpc-4183	104	15	elevated	elevate	VERB
dpc-4183	104	16	in	in	ADP
dpc-4183	104	17	cell	cell	NOUN
dpc-4183	104	18	death	death	NOUN
dpc-4183	104	19	and	and	CCONJ
dpc-4183	104	20	promote	promote	VERB
dpc-4183	104	21	inflammation	inflammation	NOUN
dpc-4183	104	22	,	,	PUNCT
dpc-4183	104	23	serum	serum	NOUN
dpc-4183	104	24	calprotectin	calprotectin	NOUN
dpc-4183	104	25	levels	level	NOUN
dpc-4183	104	26	would	would	AUX
dpc-4183	104	27	be	be	AUX
dpc-4183	104	28	expected	expect	VERB
dpc-4183	104	29	to	to	PART
dpc-4183	104	30	be	be	AUX
dpc-4183	104	31	high	high	ADJ
dpc-4183	104	32	in	in	ADP
dpc-4183	104	33	vitiligo	vitiligo	ADJ
dpc-4183	104	34	patients	patient	NOUN
dpc-4183	104	35	in	in	ADP
dpc-4183	104	36	the	the	DET
dpc-4183	104	37	active	active	ADJ
dpc-4183	104	38	phase	phase	NOUN
dpc-4183	104	39	.	.	PUNCT
dpc-4183	105	1	the	the	DET
dpc-4183	105	2	study	study	NOUN
dpc-4183	105	3	is	be	AUX
dpc-4183	105	4	limited	limit	VERB
dpc-4183	105	5	by	by	ADP
dpc-4183	105	6	its	its	PRON
dpc-4183	105	7	small	small	ADJ
dpc-4183	105	8	sample	sample	NOUN
dpc-4183	105	9	size	size	NOUN
dpc-4183	105	10	,	,	PUNCT
dpc-4183	105	11	the	the	DET
dpc-4183	105	12	use	use	NOUN
dpc-4183	105	13	of	of	ADP
dpc-4183	105	14	only	only	ADV
dpc-4183	105	15	one	one	NUM
dpc-4183	105	16	research	research	NOUN
dpc-4183	105	17	method	method	NOUN
dpc-4183	105	18	(	(	PUNCT
dpc-4183	105	19	i.e.	i.e.	X
dpc-4183	105	20	,	,	PUNCT
dpc-4183	105	21	elisa	elisa	NOUN
dpc-4183	105	22	)	)	PUNCT
dpc-4183	105	23	,	,	PUNCT
dpc-4183	105	24	and	and	CCONJ
dpc-4183	105	25	the	the	DET
dpc-4183	105	26	limited	limited	ADJ
dpc-4183	105	27	number	number	NOUN
dpc-4183	105	28	of	of	ADP
dpc-4183	105	29	patients	patient	NOUN
dpc-4183	105	30	in	in	ADP
dpc-4183	105	31	the	the	DET
dpc-4183	105	32	vitiligo	vitiligo	NOUN
dpc-4183	105	33	subgroups	subgroup	NOUN
dpc-4183	105	34	.	.	PUNCT
dpc-4183	106	1	conclusion	conclusion	VERB
dpc-4183	106	2	our	our	PRON
dpc-4183	106	3	findings	finding	NOUN
dpc-4183	106	4	and	and	CCONJ
dpc-4183	106	5	the	the	DET
dpc-4183	106	6	existing	exist	VERB
dpc-4183	106	7	literature	literature	NOUN
dpc-4183	106	8	on	on	ADP
dpc-4183	106	9	calprotectin	calprotectin	NOUN
dpc-4183	106	10	suggest	suggest	VERB
dpc-4183	106	11	its	its	PRON
dpc-4183	106	12	potential	potential	ADJ
dpc-4183	106	13	involvement	involvement	NOUN
dpc-4183	106	14	in	in	ADP
dpc-4183	106	15	the	the	DET
dpc-4183	106	16	pathogenesis	pathogenesis	NOUN
dpc-4183	106	17	of	of	ADP
dpc-4183	106	18	vitiligo	vitiligo	NOUN
dpc-4183	106	19	,	,	PUNCT
dpc-4183	106	20	independent	independent	ADJ
dpc-4183	106	21	of	of	ADP
dpc-4183	106	22	disease	disease	NOUN
dpc-4183	106	23	progression	progression	NOUN
dpc-4183	106	24	and	and	CCONJ
dpc-4183	106	25	patient	patient	ADJ
dpc-4183	106	26	characteristics	characteristic	NOUN
dpc-4183	106	27	.	.	PUNCT
dpc-4183	107	1	however	however	ADV
dpc-4183	107	2	,	,	PUNCT
dpc-4183	107	3	further	further	ADJ
dpc-4183	107	4	investigation	investigation	NOUN
dpc-4183	107	5	is	be	AUX
dpc-4183	107	6	required	require	VERB
dpc-4183	107	7	to	to	PART
dpc-4183	107	8	determine	determine	VERB
dpc-4183	107	9	its	its	PRON
dpc-4183	107	10	impact	impact	NOUN
dpc-4183	107	11	on	on	ADP
dpc-4183	107	12	autoimmunity	autoimmunity	NOUN
dpc-4183	107	13	and	and	CCONJ
dpc-4183	107	14	potential	potential	ADJ
dpc-4183	107	15	oxidative	oxidative	ADJ
dpc-4183	107	16	effects	effect	NOUN
dpc-4183	107	17	on	on	ADP
dpc-4183	107	18	the	the	DET
dpc-4183	107	19	progression	progression	NOUN
dpc-4183	107	20	of	of	ADP
dpc-4183	107	21	the	the	DET
dpc-4183	107	22	disease	disease	NOUN
dpc-4183	107	23	.	.	PUNCT
dpc-4183	108	1	this	this	DET
dpc-4183	108	2	study	study	NOUN
dpc-4183	108	3	is	be	AUX
dpc-4183	108	4	expected	expect	VERB
dpc-4183	108	5	to	to	PART
dpc-4183	108	6	facilitate	facilitate	VERB
dpc-4183	108	7	further	further	ADJ
dpc-4183	108	8	research	research	NOUN
dpc-4183	108	9	,	,	PUNCT
dpc-4183	108	10	thereby	thereby	ADV
dpc-4183	108	11	contributing	contribute	VERB
dpc-4183	108	12	to	to	ADP
dpc-4183	108	13	the	the	DET
dpc-4183	108	14	understanding	understanding	NOUN
dpc-4183	108	15	of	of	ADP
dpc-4183	108	16	the	the	DET
dpc-4183	108	17	causes	cause	NOUN
dpc-4183	108	18	and	and	CCONJ
dpc-4183	108	19	development	development	NOUN
dpc-4183	108	20	of	of	ADP
dpc-4183	108	21	vitiligo	vitiligo	NOUN
dpc-4183	108	22	,	,	PUNCT
dpc-4183	108	23	and	and	CCONJ
dpc-4183	108	24	the	the	DET
dpc-4183	108	25	creation	creation	NOUN
dpc-4183	108	26	of	of	ADP
dpc-4183	108	27	new	new	ADJ
dpc-4183	108	28	therapeutic	therapeutic	ADJ
dpc-4183	108	29	agents	agent	NOUN
dpc-4183	108	30	.	.	PUNCT
dpc-4183	109	1	references	reference	NOUN
dpc-4183	109	2	1	1	NUM
dpc-4183	109	3	.	.	PUNCT
dpc-4183	110	1	alikhan	alikhan	PROPN
dpc-4183	110	2	a	a	DET
dpc-4183	110	3	,	,	PUNCT
dpc-4183	110	4	felsten	felsten	ADJ
dpc-4183	110	5	lm	lm	PROPN
dpc-4183	110	6	,	,	PUNCT
dpc-4183	110	7	daly	daly	PROPN
dpc-4183	110	8	m	m	PROPN
dpc-4183	110	9	,	,	PUNCT
dpc-4183	110	10	petronic	petronic	ADJ
dpc-4183	110	11	-	-	PUNCT
dpc-4183	110	12	rosic	rosic	NOUN
dpc-4183	110	13	v.	v.	ADP
dpc-4183	110	14	vitiligo	vitiligo	NOUN
dpc-4183	110	15	:	:	PUNCT
dpc-4183	110	16	a	a	DET
dpc-4183	110	17	comprehensive	comprehensive	ADJ
dpc-4183	110	18	overview	overview	NOUN
dpc-4183	110	19	part	part	NOUN
dpc-4183	110	20	i.	i.	NOUN
dpc-4183	110	21	introduction	introduction	NOUN
dpc-4183	110	22	,	,	PUNCT
dpc-4183	110	23	epidemiology	epidemiology	NOUN
dpc-4183	110	24	,	,	PUNCT
dpc-4183	110	25	quality	quality	NOUN
dpc-4183	110	26	of	of	ADP
dpc-4183	110	27	life	life	NOUN
dpc-4183	110	28	,	,	PUNCT
dpc-4183	110	29	diagnosis	diagnosis	NOUN
dpc-4183	110	30	,	,	PUNCT
dpc-4183	110	31	differential	differential	ADJ
dpc-4183	110	32	diagnosis	diagnosis	NOUN
dpc-4183	110	33	,	,	PUNCT
dpc-4183	110	34	associations	association	NOUN
dpc-4183	110	35	,	,	PUNCT
dpc-4183	110	36	histopathology	histopathology	NOUN
dpc-4183	110	37	,	,	PUNCT
dpc-4183	110	38	etiology	etiology	NOUN
dpc-4183	110	39	,	,	PUNCT
dpc-4183	110	40	and	and	CCONJ
dpc-4183	110	41	work	work	NOUN
dpc-4183	110	42	-	-	PUNCT
dpc-4183	110	43	up	up	NOUN
dpc-4183	110	44	.	.	PUNCT
dpc-4183	111	1	j	j	PROPN
dpc-4183	111	2	am	be	AUX
dpc-4183	111	3	acad	acad	ADJ
dpc-4183	111	4	dermatol	dermatol	NOUN
dpc-4183	111	5	.	.	PUNCT
dpc-4183	112	1	2011;65(3):473	2011;65(3):473	NUM
dpc-4183	112	2	-	-	PUNCT
dpc-4183	112	3	91	91	NUM
dpc-4183	112	4	.	.	PUNCT
dpc-4183	113	1	2	2	X
dpc-4183	113	2	.	.	X
dpc-4183	113	3	bergqvist	bergqvist	PROPN
dpc-4183	113	4	c	c	PROPN
dpc-4183	113	5	,	,	PUNCT
dpc-4183	113	6	ezzedine	ezzedine	PROPN
dpc-4183	113	7	k.	k.	PROPN
dpc-4183	113	8	vitiligo	vitiligo	PROPN
dpc-4183	113	9	:	:	PUNCT
dpc-4183	113	10	a	a	DET
dpc-4183	113	11	review	review	NOUN
dpc-4183	113	12	.	.	PUNCT
dpc-4183	114	1	dermatology	dermatology	NOUN
dpc-4183	114	2	.	.	PUNCT
dpc-4183	115	1	2020	2020	NUM
dpc-4183	115	2	;	;	PUNCT
dpc-4183	115	3	236(6):571	236(6):571	NUM
dpc-4183	115	4	-	-	SYM
dpc-4183	115	5	92	92	NUM
dpc-4183	115	6	.	.	PUNCT
dpc-4183	116	1	3	3	X
dpc-4183	116	2	.	.	X
dpc-4183	116	3	lapeere	lapeere	PROPN
dpc-4183	116	4	h	h	NOUN
dpc-4183	116	5	,	,	PUNCT
dpc-4183	116	6	boone	boone	PROPN
dpc-4183	116	7	b	b	PROPN
dpc-4183	116	8	,	,	PUNCT
dpc-4183	116	9	de	de	X
dpc-4183	116	10	schepper	schepper	NOUN
dpc-4183	116	11	s	s	PROPN
dpc-4183	116	12	,	,	PUNCT
dpc-4183	116	13	et	et	PROPN
dpc-4183	116	14	al	al	PROPN
dpc-4183	116	15	.	.	PUNCT
dpc-4183	116	16	  	  	SPACE
dpc-4183	116	17	chapter	chapter	NOUN
dpc-4183	116	18	75	75	NUM
dpc-4183	116	19	.	.	PUNCT
dpc-4183	117	1	hypomelanoses	hypomelanose	NOUN
dpc-4183	117	2	and	and	CCONJ
dpc-4183	117	3	hypermelanoses	hypermelanose	NOUN
dpc-4183	117	4	.	.	PUNCT
dpc-4183	117	5	 	 	SPACE
dpc-4183	117	6	in	in	ADP
dpc-4183	117	7	:	:	PUNCT
dpc-4183	117	8	 	 	SPACE
dpc-4183	117	9	goldsmith	goldsmith	PROPN
dpc-4183	117	10	la	la	PROPN
dpc-4183	117	11	,	,	PUNCT
dpc-4183	117	12	katz	katz	PROPN
dpc-4183	117	13	si	si	PROPN
dpc-4183	117	14	,	,	PUNCT
dpc-4183	117	15	gilchrest	gilchr	ADJ
dpc-4183	117	16	ba	ba	NOUN
dpc-4183	117	17	,	,	PUNCT
dpc-4183	117	18	paller	paller	NOUN
dpc-4183	117	19	as	as	ADP
dpc-4183	117	20	,	,	PUNCT
dpc-4183	117	21	leffell	leffell	PROPN
dpc-4183	117	22	dj	dj	PROPN
dpc-4183	117	23	,	,	PUNCT
dpc-4183	117	24	wolff	wolff	PROPN
dpc-4183	117	25	k.	k.	PROPN
dpc-4183	117	26	  	  	SPACE
dpc-4183	117	27	eds	ed	NOUN
dpc-4183	117	28	.	.	PUNCT
dpc-4183	117	29	  	  	SPACE
dpc-4183	117	30	fitzpatrick	fitzpatrick	PROPN
dpc-4183	117	31	’s	’s	PART
dpc-4183	117	32	dermatology	dermatology	NOUN
dpc-4183	117	33	in	in	ADP
dpc-4183	117	34	general	general	ADJ
dpc-4183	117	35	medicine	medicine	NOUN
dpc-4183	117	36	,	,	PUNCT
dpc-4183	117	37	8e	8e	NUM
dpc-4183	117	38	.	.	PUNCT
dpc-4183	118	1	the	the	DET
dpc-4183	118	2	mcgraw	mcgraw	PROPN
dpc-4183	118	3	-	-	PUNCT
dpc-4183	118	4	hill	hill	NOUN
dpc-4183	118	5	companies	company	NOUN
dpc-4183	118	6	;	;	PUNCT
dpc-4183	118	7	2012.:804	2012.:804	NUM
dpc-4183	118	8	-	-	SYM
dpc-4183	118	9	26	26	NUM
dpc-4183	118	10	.	.	PUNCT
dpc-4183	119	1	4	4	NUM
dpc-4183	119	2	.	.	X
dpc-4183	119	3	ortonne	ortonne	VERB
dpc-4183	119	4	tpaj	tpaj	NOUN
dpc-4183	119	5	-	-	PUNCT
dpc-4183	119	6	p.	p.	NOUN
dpc-4183	119	7	vitiligo	vitiligo	NOUN
dpc-4183	119	8	and	and	CCONJ
dpc-4183	119	9	other	other	ADJ
dpc-4183	119	10	disorders	disorder	NOUN
dpc-4183	119	11	of	of	ADP
dpc-4183	119	12	hypopigmentation	hypopigmentation	NOUN
dpc-4183	119	13	.	.	PUNCT
dpc-4183	120	1	in	in	ADP
dpc-4183	120	2	:	:	PUNCT
dpc-4183	120	3	jean	jean	PROPN
dpc-4183	120	4	l.	l.	PROPN
dpc-4183	120	5	bolognia	bolognia	PROPN
dpc-4183	120	6	julie	julie	PROPN
dpc-4183	120	7	v.	v.	PROPN
dpc-4183	120	8	schaffer	schaffer	PROPN
dpc-4183	120	9	,	,	PUNCT
dpc-4183	120	10	lorenzo	lorenzo	NOUN
dpc-4183	120	11	cerroni	cerroni	NOUN
dpc-4183	120	12	,	,	PUNCT
dpc-4183	120	13	editors	editor	NOUN
dpc-4183	120	14	.	.	PUNCT
dpc-4183	121	1	dermatology	dermatology	NOUN
dpc-4183	121	2	4e	4e	NOUN
dpc-4183	121	3	.	.	PUNCT
dpc-4183	122	1	elsevier;2018:1087	elsevier;2018:1087	X
dpc-4183	122	2	-	-	PUNCT
dpc-4183	122	3	114	114	NUM
dpc-4183	122	4	.	.	PUNCT
dpc-4183	123	1	5	5	NUM
dpc-4183	123	2	.	.	X
dpc-4183	123	3	marchioro	marchioro	PROPN
dpc-4183	123	4	hz	hz	PROPN
dpc-4183	123	5	,	,	PUNCT
dpc-4183	123	6	silva	silva	PROPN
dpc-4183	123	7	de	de	PROPN
dpc-4183	123	8	castro	castro	PROPN
dpc-4183	123	9	cc	cc	PROPN
dpc-4183	123	10	,	,	PUNCT
dpc-4183	123	11	fava	fava	PROPN
dpc-4183	123	12	vm	vm	PROPN
dpc-4183	123	13	,	,	PUNCT
dpc-4183	123	14	sakiyama	sakiyama	NOUN
dpc-4183	123	15	ph	ph	PROPN
dpc-4183	123	16	,	,	PUNCT
dpc-4183	123	17	dellatorre	dellatorre	NOUN
dpc-4183	123	18	g	g	NOUN
dpc-4183	123	19	,	,	PUNCT
dpc-4183	123	20	miot	miot	NOUN
dpc-4183	123	21	ha	ha	INTJ
dpc-4183	123	22	.	.	PROPN
dpc-4183	123	23	update	update	NOUN
dpc-4183	123	24	on	on	ADP
dpc-4183	123	25	the	the	DET
dpc-4183	123	26	pathogenesis	pathogenesis	NOUN
dpc-4183	123	27	of	of	ADP
dpc-4183	123	28	vitiligo	vitiligo	NOUN
dpc-4183	123	29	.	.	PUNCT
dpc-4183	124	1	an	an	DET
dpc-4183	124	2	bras	bras	NOUN
dpc-4183	124	3	dermatol	dermatol	NOUN
dpc-4183	124	4	.	.	PUNCT
dpc-4183	125	1	2022;97(4):478	2022;97(4):478	NUM
dpc-4183	125	2	-	-	SYM
dpc-4183	125	3	90	90	NUM
dpc-4183	125	4	.	.	PUNCT
dpc-4183	126	1	whether	whether	SCONJ
dpc-4183	126	2	released	release	VERB
dpc-4183	126	3	from	from	ADP
dpc-4183	126	4	or	or	CCONJ
dpc-4183	126	5	found	find	VERB
dpc-4183	126	6	in	in	ADP
dpc-4183	126	7	these	these	DET
dpc-4183	126	8	cells	cell	NOUN
dpc-4183	126	9	,	,	PUNCT
dpc-4183	126	10	might	might	AUX
dpc-4183	126	11	be	be	AUX
dpc-4183	126	12	involved	involve	VERB
dpc-4183	126	13	in	in	ADP
dpc-4183	126	14	the	the	DET
dpc-4183	126	15	pathogenesis	pathogenesis	NOUN
dpc-4183	126	16	[	[	X
dpc-4183	126	17	14	14	NUM
dpc-4183	126	18	]	]	PUNCT
dpc-4183	126	19	.	.	PUNCT
dpc-4183	127	1	in	in	ADP
dpc-4183	127	2	the	the	DET
dpc-4183	127	3	literature	literature	NOUN
dpc-4183	127	4	,	,	PUNCT
dpc-4183	127	5	calprotectin	calprotectin	NOUN
dpc-4183	127	6	has	have	AUX
dpc-4183	127	7	also	also	ADV
dpc-4183	127	8	been	be	AUX
dpc-4183	127	9	investigated	investigate	VERB
dpc-4183	127	10	in	in	ADP
dpc-4183	127	11	autoimmune	autoimmune	ADJ
dpc-4183	127	12	diseases	disease	NOUN
dpc-4183	127	13	.	.	PUNCT
dpc-4183	128	1	in	in	ADP
dpc-4183	128	2	acquired	acquire	VERB
dpc-4183	128	3	epidermolysis	epidermolysis	NOUN
dpc-4183	128	4	bullosa	bullosa	NOUN
dpc-4183	128	5	(	(	PUNCT
dpc-4183	128	6	eb	eb	PROPN
dpc-4183	128	7	)	)	PUNCT
dpc-4183	128	8	and	and	CCONJ
dpc-4183	128	9	bullous	bullous	ADJ
dpc-4183	128	10	pemphigoid	pemphigoid	NOUN
dpc-4183	128	11	(	(	PUNCT
dpc-4183	128	12	bp	bp	PROPN
dpc-4183	128	13	)	)	PUNCT
dpc-4183	128	14	,	,	PUNCT
dpc-4183	128	15	the	the	DET
dpc-4183	128	16	mrp	mrp	PROPN
dpc-4183	128	17	8/14	8/14	NUM
dpc-4183	128	18	(	(	PUNCT
dpc-4183	128	19	calprotectin	calprotectin	NOUN
dpc-4183	128	20	)	)	PUNCT
dpc-4183	128	21	protein	protein	NOUN
dpc-4183	128	22	was	be	AUX
dpc-4183	128	23	observed	observe	VERB
dpc-4183	128	24	to	to	PART
dpc-4183	128	25	be	be	AUX
dpc-4183	128	26	elevated	elevate	VERB
dpc-4183	128	27	in	in	ADP
dpc-4183	128	28	serum	serum	NOUN
dpc-4183	128	29	in	in	ADP
dpc-4183	128	30	comparison	comparison	NOUN
dpc-4183	128	31	to	to	ADP
dpc-4183	128	32	the	the	DET
dpc-4183	128	33	control	control	NOUN
dpc-4183	128	34	group	group	NOUN
dpc-4183	128	35	.	.	PUNCT
dpc-4183	129	1	an	an	DET
dpc-4183	129	2	experimental	experimental	ADJ
dpc-4183	129	3	study	study	NOUN
dpc-4183	129	4	was	be	AUX
dpc-4183	129	5	also	also	ADV
dpc-4183	129	6	conducted	conduct	VERB
dpc-4183	129	7	on	on	ADP
dpc-4183	129	8	mice	mouse	NOUN
dpc-4183	129	9	in	in	ADP
dpc-4183	129	10	same	same	ADJ
dpc-4183	129	11	study	study	NOUN
dpc-4183	129	12	,	,	PUNCT
dpc-4183	129	13	and	and	CCONJ
dpc-4183	129	14	it	it	PRON
dpc-4183	129	15	was	be	AUX
dpc-4183	129	16	stated	state	VERB
dpc-4183	129	17	that	that	SCONJ
dpc-4183	129	18	calprotectin	calprotectin	NOUN
dpc-4183	129	19	did	do	AUX
dpc-4183	129	20	not	not	PART
dpc-4183	129	21	have	have	VERB
dpc-4183	129	22	a	a	DET
dpc-4183	129	23	role	role	NOUN
dpc-4183	129	24	in	in	ADP
dpc-4183	129	25	the	the	DET
dpc-4183	129	26	effector	effector	NOUN
dpc-4183	129	27	phase	phase	NOUN
dpc-4183	129	28	of	of	ADP
dpc-4183	129	29	eb	eb	PROPN
dpc-4183	129	30	and	and	CCONJ
dpc-4183	129	31	bp	bp	PROPN
dpc-4183	129	32	but	but	CCONJ
dpc-4183	129	33	could	could	AUX
dpc-4183	129	34	potentially	potentially	ADV
dpc-4183	129	35	have	have	VERB
dpc-4183	129	36	a	a	DET
dpc-4183	129	37	role	role	NOUN
dpc-4183	129	38	in	in	ADP
dpc-4183	129	39	the	the	DET
dpc-4183	129	40	initial	initial	ADJ
dpc-4183	129	41	phase	phase	NOUN
dpc-4183	129	42	[	[	X
dpc-4183	129	43	15	15	NUM
dpc-4183	129	44	]	]	PUNCT
dpc-4183	129	45	.	.	PUNCT
dpc-4183	130	1	in	in	ADP
dpc-4183	130	2	a	a	DET
dpc-4183	130	3	study	study	NOUN
dpc-4183	130	4	of	of	ADP
dpc-4183	130	5	cutaneous	cutaneous	ADJ
dpc-4183	130	6	lupus	lupus	PROPN
dpc-4183	130	7	erythematosus	erythematosus	NOUN
dpc-4183	130	8	,	,	PUNCT
dpc-4183	130	9	loser	loser	PROPN
dpc-4183	130	10	et	et	PROPN
dpc-4183	130	11	  	  	SPACE
dpc-4183	130	12	al	al	PROPN
dpc-4183	130	13	.	.	PROPN
dpc-4183	130	14	concluded	conclude	VERB
dpc-4183	130	15	that	that	SCONJ
dpc-4183	130	16	mrp	mrp	PROPN
dpc-4183	130	17	8/14	8/14	NUM
dpc-4183	130	18	had	have	VERB
dpc-4183	130	19	a	a	DET
dpc-4183	130	20	crucial	crucial	ADJ
dpc-4183	130	21	role	role	NOUN
dpc-4183	130	22	in	in	ADP
dpc-4183	130	23	the	the	DET
dpc-4183	130	24	development	development	NOUN
dpc-4183	130	25	of	of	ADP
dpc-4183	130	26	auto	auto	NOUN
dpc-4183	130	27	-	-	PUNCT
dpc-4183	130	28	reactive	reactive	NOUN
dpc-4183	130	29	cd8	cd8	PROPN
dpc-4183	130	30	+	+	PROPN
dpc-4183	130	31	t	t	NOUN
dpc-4183	130	32	cells	cell	NOUN
dpc-4183	130	33	in	in	ADP
dpc-4183	130	34	a	a	DET
dpc-4183	130	35	model	model	NOUN
dpc-4183	130	36	of	of	ADP
dpc-4183	130	37	cutaneous	cutaneous	ADJ
dpc-4183	130	38	lupus	lupus	ADJ
dpc-4183	130	39	erythematosus	erythematosus	NOUN
dpc-4183	131	1	[	[	X
dpc-4183	131	2	16	16	NUM
dpc-4183	131	3	]	]	PUNCT
dpc-4183	131	4	.	.	PUNCT
dpc-4183	132	1	on	on	ADP
dpc-4183	132	2	the	the	DET
dpc-4183	132	3	other	other	ADJ
dpc-4183	132	4	hand	hand	NOUN
dpc-4183	132	5	,	,	PUNCT
dpc-4183	132	6	petersen	petersen	PROPN
dpc-4183	132	7	et	et	PROPN
dpc-4183	132	8	al	al	PROPN
dpc-4183	132	9	.	.	PROPN
dpc-4183	132	10	described	describe	VERB
dpc-4183	132	11	the	the	DET
dpc-4183	132	12	effect	effect	NOUN
dpc-4183	132	13	of	of	ADP
dpc-4183	132	14	calprotectin	calprotectin	NOUN
dpc-4183	132	15	on	on	ADP
dpc-4183	132	16	the	the	DET
dpc-4183	132	17	maturation	maturation	NOUN
dpc-4183	132	18	of	of	ADP
dpc-4183	132	19	dendritic	dendritic	ADJ
dpc-4183	132	20	cells	cell	NOUN
dpc-4183	132	21	in	in	ADP
dpc-4183	132	22	experimental	experimental	ADJ
dpc-4183	132	23	allergic	allergic	ADJ
dpc-4183	132	24	contact	contact	NOUN
dpc-4183	132	25	dermatitis	dermatitis	NOUN
dpc-4183	132	26	[	[	X
dpc-4183	132	27	17	17	NUM
dpc-4183	132	28	]	]	PUNCT
dpc-4183	132	29	.	.	PUNCT
dpc-4183	133	1	based	base	VERB
dpc-4183	133	2	on	on	ADP
dpc-4183	133	3	the	the	DET
dpc-4183	133	4	induction	induction	NOUN
dpc-4183	133	5	of	of	ADP
dpc-4183	133	6	auto	auto	NOUN
dpc-4183	133	7	-	-	PUNCT
dpc-4183	133	8	reactive	reactive	NOUN
dpc-4183	133	9	cd8	cd8	PROPN
dpc-4183	133	10	+	+	PROPN
dpc-4183	133	11	t	t	NOUN
dpc-4183	133	12	cells	cell	NOUN
dpc-4183	133	13	by	by	ADP
dpc-4183	133	14	calprotectin	calprotectin	NOUN
dpc-4183	133	15	in	in	ADP
dpc-4183	133	16	patients	patient	NOUN
dpc-4183	133	17	with	with	ADP
dpc-4183	133	18	myasthenia	myasthenia	PROPN
dpc-4183	133	19	gravis	gravis	NOUN
dpc-4183	133	20	,	,	PUNCT
dpc-4183	133	21	serum	serum	NOUN
dpc-4183	133	22	calprotectin	calprotectin	NOUN
dpc-4183	133	23	levels	level	NOUN
dpc-4183	133	24	were	be	AUX
dpc-4183	133	25	investigated	investigate	VERB
dpc-4183	133	26	,	,	PUNCT
dpc-4183	133	27	with	with	ADP
dpc-4183	133	28	the	the	DET
dpc-4183	133	29	results	result	NOUN
dpc-4183	133	30	showing	show	VERB
dpc-4183	133	31	that	that	SCONJ
dpc-4183	133	32	the	the	DET
dpc-4183	133	33	levels	level	NOUN
dpc-4183	133	34	in	in	ADP
dpc-4183	133	35	myasthenia	myasthenia	NOUN
dpc-4183	133	36	gravis	gravis	NOUN
dpc-4183	133	37	patients	patient	NOUN
dpc-4183	133	38	were	be	AUX
dpc-4183	133	39	higher	high	ADJ
dpc-4183	133	40	compared	compare	VERB
dpc-4183	133	41	to	to	ADP
dpc-4183	133	42	the	the	DET
dpc-4183	133	43	control	control	NOUN
dpc-4183	133	44	group	group	NOUN
dpc-4183	133	45	[	[	X
dpc-4183	133	46	18	18	NUM
dpc-4183	133	47	]	]	PUNCT
dpc-4183	133	48	.	.	PUNCT
dpc-4183	134	1	in	in	ADP
dpc-4183	134	2	our	our	PRON
dpc-4183	134	3	study	study	NOUN
dpc-4183	134	4	,	,	PUNCT
dpc-4183	134	5	serum	serum	NOUN
dpc-4183	134	6	calprotectin	calprotectin	NOUN
dpc-4183	134	7	levels	level	NOUN
dpc-4183	134	8	in	in	ADP
dpc-4183	134	9	vitiligo	vitiligo	ADJ
dpc-4183	134	10	patients	patient	NOUN
dpc-4183	134	11	were	be	AUX
dpc-4183	134	12	found	find	VERB
dpc-4183	134	13	to	to	PART
dpc-4183	134	14	be	be	AUX
dpc-4183	134	15	significantly	significantly	ADV
dpc-4183	134	16	higher	high	ADJ
dpc-4183	134	17	than	than	ADP
dpc-4183	134	18	in	in	ADP
dpc-4183	134	19	the	the	DET
dpc-4183	134	20	control	control	NOUN
dpc-4183	134	21	group	group	NOUN
dpc-4183	134	22	.	.	PUNCT
dpc-4183	135	1	in	in	ADP
dpc-4183	135	2	a	a	DET
dpc-4183	135	3	study	study	NOUN
dpc-4183	135	4	investigating	investigate	VERB
dpc-4183	135	5	s100b	s100b	PROPN
dpc-4183	135	6	protein	protein	NOUN
dpc-4183	135	7	,	,	PUNCT
dpc-4183	135	8	which	which	PRON
dpc-4183	135	9	has	have	VERB
dpc-4183	135	10	a	a	DET
dpc-4183	135	11	damp	damp	ADJ
dpc-4183	135	12	function	function	NOUN
dpc-4183	135	13	like	like	ADP
dpc-4183	135	14	calprotectin	calprotectin	NOUN
dpc-4183	135	15	and	and	CCONJ
dpc-4183	135	16	is	be	AUX
dpc-4183	135	17	thought	think	VERB
dpc-4183	135	18	to	to	PART
dpc-4183	135	19	be	be	AUX
dpc-4183	135	20	responsible	responsible	ADJ
dpc-4183	135	21	for	for	ADP
dpc-4183	135	22	cytotoxicity	cytotoxicity	NOUN
dpc-4183	135	23	in	in	ADP
dpc-4183	135	24	vitiligo	vitiligo	NOUN
dpc-4183	135	25	,	,	PUNCT
dpc-4183	135	26	serum	serum	NOUN
dpc-4183	135	27	s100b	s100b	PROPN
dpc-4183	135	28	protein	protein	NOUN
dpc-4183	135	29	was	be	AUX
dpc-4183	135	30	found	find	VERB
dpc-4183	135	31	to	to	PART
dpc-4183	135	32	be	be	AUX
dpc-4183	135	33	significantly	significantly	ADV
dpc-4183	135	34	higher	high	ADJ
dpc-4183	135	35	in	in	ADP
dpc-4183	135	36	vitiligo	vitiligo	ADJ
dpc-4183	135	37	patients	patient	NOUN
dpc-4183	135	38	compared	compare	VERB
dpc-4183	135	39	to	to	ADP
dpc-4183	135	40	the	the	DET
dpc-4183	135	41	control	control	NOUN
dpc-4183	135	42	group	group	NOUN
dpc-4183	135	43	,	,	PUNCT
dpc-4183	135	44	and	and	CCONJ
dpc-4183	135	45	no	no	DET
dpc-4183	135	46	correlation	correlation	NOUN
dpc-4183	135	47	was	be	AUX
dpc-4183	135	48	found	find	VERB
dpc-4183	135	49	with	with	ADP
dpc-4183	135	50	disease	disease	NOUN
dpc-4183	135	51	activity	activity	NOUN
dpc-4183	135	52	or	or	CCONJ
dpc-4183	135	53	vasi	vasi	PROPN
dpc-4183	135	54	-	-	PUNCT
dpc-4183	135	55	vida	vida	PROPN
dpc-4183	135	56	scores	score	NOUN
dpc-4183	135	57	[	[	X
dpc-4183	135	58	19	19	NUM
dpc-4183	135	59	]	]	PUNCT
dpc-4183	135	60	.	.	PUNCT
dpc-4183	136	1	in	in	ADP
dpc-4183	136	2	our	our	PRON
dpc-4183	136	3	study	study	NOUN
dpc-4183	136	4	,	,	PUNCT
dpc-4183	136	5	no	no	DET
dpc-4183	136	6	correlation	correlation	NOUN
dpc-4183	136	7	was	be	AUX
dpc-4183	136	8	found	find	VERB
dpc-4183	136	9	between	between	ADP
dpc-4183	136	10	calprotectin	calprotectin	NOUN
dpc-4183	136	11	and	and	CCONJ
dpc-4183	136	12	vasi	vasi	PROPN
dpc-4183	136	13	-	-	PUNCT
dpc-4183	136	14	vida	vida	PROPN
dpc-4183	136	15	scores	score	NOUN
dpc-4183	136	16	.	.	PUNCT
dpc-4183	137	1	furthermore	furthermore	ADV
dpc-4183	137	2	,	,	PUNCT
dpc-4183	137	3	there	there	PRON
dpc-4183	137	4	was	be	VERB
dpc-4183	137	5	no	no	DET
dpc-4183	137	6	correlation	correlation	NOUN
dpc-4183	137	7	noted	note	VERB
dpc-4183	137	8	between	between	ADP
dpc-4183	137	9	serum	serum	NOUN
dpc-4183	137	10	calprotectin	calprotectin	NOUN
dpc-4183	137	11	level	level	NOUN
dpc-4183	137	12	and	and	CCONJ
dpc-4183	137	13	family	family	NOUN
dpc-4183	137	14	history	history	NOUN
dpc-4183	137	15	,	,	PUNCT
dpc-4183	137	16	presence	presence	NOUN
dpc-4183	137	17	of	of	ADP
dpc-4183	137	18	leukotrichia	leukotrichia	NOUN
dpc-4183	137	19	,	,	PUNCT
dpc-4183	137	20	body	body	NOUN
dpc-4183	137	21	mass	mass	PROPN
dpc-4183	137	22	index	index	NOUN
dpc-4183	137	23	,	,	PUNCT
dpc-4183	137	24	skin	skin	NOUN
dpc-4183	137	25	phototype	phototype	NOUN
dpc-4183	137	26	,	,	PUNCT
dpc-4183	137	27	disease	disease	NOUN
dpc-4183	137	28	type	type	NOUN
dpc-4183	137	29	,	,	PUNCT
dpc-4183	137	30	age	age	NOUN
dpc-4183	137	31	,	,	PUNCT
dpc-4183	137	32	age	age	NOUN
dpc-4183	137	33	at	at	ADP
dpc-4183	137	34	onset	onset	NOUN
dpc-4183	137	35	,	,	PUNCT
dpc-4183	137	36	or	or	CCONJ
dpc-4183	137	37	duration	duration	NOUN
dpc-4183	137	38	of	of	ADP
dpc-4183	137	39	disease	disease	NOUN
dpc-4183	137	40	.	.	PUNCT
dpc-4183	138	1	this	this	PRON
dpc-4183	138	2	is	be	AUX
dpc-4183	138	3	probably	probably	ADV
dpc-4183	138	4	due	due	ADJ
dpc-4183	138	5	to	to	ADP
dpc-4183	138	6	inadequate	inadequate	ADJ
dpc-4183	138	7	sample	sample	NOUN
dpc-4183	138	8	size	size	NOUN
dpc-4183	138	9	.	.	PUNCT
dpc-4183	139	1	damage	damage	NOUN
dpc-4183	139	2	to	to	ADP
dpc-4183	139	3	melanocytes	melanocyte	NOUN
dpc-4183	139	4	results	result	NOUN
dpc-4183	139	5	from	from	ADP
dpc-4183	139	6	an	an	DET
dpc-4183	139	7	imbalance	imbalance	NOUN
dpc-4183	139	8	in	in	ADP
dpc-4183	139	9	oxidative	oxidative	ADJ
dpc-4183	139	10	stress	stress	NOUN
dpc-4183	139	11	according	accord	VERB
dpc-4183	139	12	to	to	ADP
dpc-4183	139	13	biochemical	biochemical	ADJ
dpc-4183	139	14	hypothesis	hypothesis	NOUN
dpc-4183	139	15	,	,	PUNCT
dpc-4183	139	16	and	and	CCONJ
dpc-4183	139	17	the	the	DET
dpc-4183	139	18	role	role	NOUN
dpc-4183	139	19	of	of	ADP
dpc-4183	139	20	calprotectin	calprotectin	NOUN
dpc-4183	139	21	in	in	ADP
dpc-4183	139	22	the	the	DET
dpc-4183	139	23	production	production	NOUN
dpc-4183	139	24	of	of	ADP
dpc-4183	139	25	reactive	reactive	ADJ
dpc-4183	139	26	oxygen	oxygen	NOUN
dpc-4183	139	27	radicals	radical	NOUN
dpc-4183	139	28	is	be	AUX
dpc-4183	139	29	known	know	VERB
dpc-4183	139	30	[	[	PUNCT
dpc-4183	139	31	20	20	NUM
dpc-4183	139	32	]	]	PUNCT
dpc-4183	139	33	.	.	PUNCT
dpc-4183	140	1	there	there	PRON
dpc-4183	140	2	is	be	VERB
dpc-4183	140	3	no	no	DET
dpc-4183	140	4	previous	previous	ADJ
dpc-4183	140	5	study	study	NOUN
dpc-4183	140	6	on	on	ADP
dpc-4183	140	7	calprotectin	calprotectin	NOUN
dpc-4183	140	8	,	,	PUNCT
dpc-4183	140	9	which	which	PRON
dpc-4183	140	10	has	have	VERB
dpc-4183	140	11	roles	role	NOUN
dpc-4183	140	12	in	in	ADP
dpc-4183	140	13	autoimmunity	autoimmunity	NOUN
dpc-4183	140	14	and	and	CCONJ
dpc-4183	140	15	oxidative	oxidative	ADJ
dpc-4183	140	16	stress	stress	NOUN
dpc-4183	140	17	mechanisms	mechanism	NOUN
dpc-4183	140	18	in	in	ADP
dpc-4183	140	19	vitiligo	vitiligo	NOUN
dpc-4183	140	20	.	.	PUNCT
dpc-4183	141	1	however	however	ADV
dpc-4183	141	2	,	,	PUNCT
dpc-4183	141	3	some	some	DET
dpc-4183	141	4	limited	limited	ADJ
dpc-4183	141	5	success	success	NOUN
dpc-4183	141	6	has	have	AUX
dpc-4183	141	7	been	be	AUX
dpc-4183	141	8	achieved	achieve	VERB
dpc-4183	141	9	with	with	ADP
dpc-4183	141	10	antioxidant	antioxidant	ADJ
dpc-4183	141	11	therapy	therapy	NOUN
dpc-4183	141	12	.	.	PUNCT
dpc-4183	142	1	in	in	ADP
dpc-4183	142	2	this	this	DET
dpc-4183	142	3	study	study	NOUN
dpc-4183	142	4	,	,	PUNCT
dpc-4183	142	5	serum	serum	NOUN
dpc-4183	142	6	calprotectin	calprotectin	NOUN
dpc-4183	142	7	levels	level	NOUN
dpc-4183	142	8	were	be	AUX
dpc-4183	142	9	found	find	VERB
dpc-4183	142	10	to	to	PART
dpc-4183	142	11	be	be	AUX
dpc-4183	142	12	elevated	elevate	VERB
dpc-4183	142	13	in	in	ADP
dpc-4183	142	14	people	people	NOUN
dpc-4183	142	15	who	who	PRON
dpc-4183	142	16	had	have	AUX
dpc-4183	142	17	received	receive	VERB
dpc-4183	142	18	any	any	DET
dpc-4183	142	19	form	form	NOUN
dpc-4183	142	20	of	of	ADP
dpc-4183	142	21	treatment	treatment	NOUN
dpc-4183	142	22	within	within	ADP
dpc-4183	142	23	the	the	DET
dpc-4183	142	24	previous	previous	ADJ
dpc-4183	142	25	six	six	NUM
dpc-4183	142	26	table	table	NOUN
dpc-4183	142	27	4	4	NUM
dpc-4183	142	28	.	.	PUNCT
dpc-4183	142	29	statistical	statistical	ADJ
dpc-4183	142	30	results	result	NOUN
dpc-4183	142	31	of	of	ADP
dpc-4183	142	32	roc	roc	NOUN
dpc-4183	142	33	analysis	analysis	NOUN
dpc-4183	142	34	variable	variable	ADJ
dpc-4183	142	35	auc	auc	NOUN
dpc-4183	142	36	standard	standard	ADJ
dpc-4183	142	37	error	error	NOUN
dpc-4183	142	38	p	p	NOUN
dpc-4183	142	39	value	value	NOUN
dpc-4183	142	40	*	*	NOUN
dpc-4183	142	41	95	95	NUM
dpc-4183	142	42	%	%	NOUN
dpc-4183	142	43	confidence	confidence	NOUN
dpc-4183	142	44	interval	interval	NOUN
dpc-4183	142	45	cutofflower	cutofflower	NOUN
dpc-4183	142	46	limit	limit	VERB
dpc-4183	142	47	upper	upper	ADJ
dpc-4183	142	48	limit	limit	NOUN
dpc-4183	142	49	calprotectin	calprotectin	VERB
dpc-4183	142	50	0.657	0.657	NUM
dpc-4183	142	51	0.062	0.062	NUM
dpc-4183	142	52	0.000	0.000	NUM
dpc-4183	142	53	0.535	0.535	NUM
dpc-4183	142	54	0.780	0.780	NUM
dpc-4183	142	55	445.64	445.64	NUM
dpc-4183	142	56	*	*	PUNCT
dpc-4183	142	57	p	p	X
dpc-4183	142	58	<	<	X
dpc-4183	142	59	0.05	0.05	NUM
dpc-4183	142	60	original	original	ADJ
dpc-4183	142	61	article	article	NOUN
dpc-4183	142	62	|	|	ADV
dpc-4183	142	63	dermatol	dermatol	ADJ
dpc-4183	142	64	pract	pract	NOUN
dpc-4183	142	65	concept	concept	NOUN
dpc-4183	142	66	.	.	PUNCT
dpc-4183	143	1	2024;14(3):e2024184	2024;14(3):e2024184	NUM
dpc-4183	143	2	5	5	NUM
dpc-4183	143	3	14	14	NUM
dpc-4183	143	4	.	.	PUNCT
dpc-4183	144	1	savas	savas	PROPN
dpc-4183	144	2	guzel	guzel	PROPN
dpc-4183	144	3	ge	ge	PROPN
dpc-4183	144	4	,	,	PUNCT
dpc-4183	144	5	mustafa	mustafa	PROPN
dpc-4183	144	6	kulac	kulac	PROPN
dpc-4183	144	7	,	,	PUNCT
dpc-4183	144	8	eda	eda	PROPN
dpc-4183	144	9	celik	celik	VERB
dpc-4183	144	10	guzel	guzel	PROPN
dpc-4183	144	11	,	,	PUNCT
dpc-4183	144	12	volkan	volkan	PROPN
dpc-4183	144	13	kucukyalcin	kucukyalcin	PROPN
dpc-4183	144	14	,	,	PUNCT
dpc-4183	144	15	sule	sule	PROPN
dpc-4183	144	16	kaya	kaya	PROPN
dpc-4183	144	17	,	,	PUNCT
dpc-4183	144	18	ali	ali	PROPN
dpc-4183	144	19	riza	riza	PROPN
dpc-4183	144	20	kiziler	kiziler	PROPN
dpc-4183	144	21	.	.	PUNCT
dpc-4183	145	1	chemerin	chemerin	NOUN
dpc-4183	145	2	and	and	CCONJ
dpc-4183	145	3	calprotectin	calprotectin	NOUN
dpc-4183	145	4	levels	level	NOUN
dpc-4183	145	5	correlate	correlate	VERB
dpc-4183	145	6	with	with	ADP
dpc-4183	145	7	disease	disease	NOUN
dpc-4183	145	8	activity	activity	NOUN
dpc-4183	145	9	and	and	CCONJ
dpc-4183	145	10	inflammation	inflammation	NOUN
dpc-4183	145	11	markers	marker	NOUN
dpc-4183	145	12	in	in	ADP
dpc-4183	145	13	psoriasis	psoriasis	NOUN
dpc-4183	145	14	vulgaris	vulgaris	NOUN
dpc-4183	145	15	.	.	PUNCT
dpc-4183	146	1	dermatologica	dermatologica	PROPN
dpc-4183	146	2	sinica	sinica	PROPN
dpc-4183	146	3	.	.	PUNCT
dpc-4183	147	1	2015;33(1):1	2015;33(1):1	NUM
dpc-4183	147	2	-	-	SYM
dpc-4183	147	3	4	4	NUM
dpc-4183	147	4	.	.	NOUN
dpc-4183	147	5	15	15	NUM
dpc-4183	147	6	.	.	PUNCT
dpc-4183	148	1	akbarzadeh	akbarzadeh	PROPN
dpc-4183	148	2	r	r	PROPN
dpc-4183	148	3	,	,	PUNCT
dpc-4183	148	4	yu	yu	PROPN
dpc-4183	148	5	x	x	PROPN
dpc-4183	148	6	,	,	PUNCT
dpc-4183	148	7	vogl	vogl	PROPN
dpc-4183	148	8	t	t	PROPN
dpc-4183	148	9	,	,	PUNCT
dpc-4183	148	10	et	et	PROPN
dpc-4183	148	11	al	al	PROPN
dpc-4183	148	12	.	.	PUNCT
dpc-4183	148	13	myeloid	myeloid	NOUN
dpc-4183	148	14	-	-	PUNCT
dpc-4183	148	15	related	relate	VERB
dpc-4183	148	16	proteins-8	proteins-8	PROPN
dpc-4183	148	17	and	and	CCONJ
dpc-4183	148	18	-14	-14	NUM
dpc-4183	148	19	are	be	AUX
dpc-4183	148	20	expressed	express	VERB
dpc-4183	148	21	but	but	CCONJ
dpc-4183	148	22	dispensable	dispensable	ADJ
dpc-4183	148	23	in	in	ADP
dpc-4183	148	24	the	the	DET
dpc-4183	148	25	pathogenesis	pathogenesis	NOUN
dpc-4183	148	26	of	of	ADP
dpc-4183	148	27	experimental	experimental	ADJ
dpc-4183	148	28	epidermolysis	epidermolysis	NOUN
dpc-4183	148	29	bullosa	bullosa	PROPN
dpc-4183	148	30	acquisita	acquisita	NOUN
dpc-4183	148	31	and	and	CCONJ
dpc-4183	148	32	bullous	bullous	ADJ
dpc-4183	148	33	pemphigoid	pemphigoid	NOUN
dpc-4183	148	34	.	.	PUNCT
dpc-4183	149	1	j	j	PROPN
dpc-4183	149	2	dermatol	dermatol	NOUN
dpc-4183	149	3	sci	sci	PROPN
dpc-4183	149	4	.	.	PUNCT
dpc-4183	149	5	2016;81(3):165	2016;81(3):165	PROPN
dpc-4183	149	6	-	-	PUNCT
dpc-4183	149	7	72	72	NUM
dpc-4183	149	8	.	.	PUNCT
dpc-4183	149	9	16	16	NUM
dpc-4183	149	10	.	.	PUNCT
dpc-4183	150	1	loser	loser	PROPN
dpc-4183	150	2	k	k	PROPN
dpc-4183	150	3	,	,	PUNCT
dpc-4183	150	4	vogl	vogl	PROPN
dpc-4183	150	5	t	t	PROPN
dpc-4183	150	6	,	,	PUNCT
dpc-4183	150	7	voskort	voskort	NOUN
dpc-4183	150	8	m	m	PROPN
dpc-4183	150	9	,	,	PUNCT
dpc-4183	150	10	et	et	PROPN
dpc-4183	150	11	al	al	PROPN
dpc-4183	150	12	.	.	PUNCT
dpc-4183	151	1	the	the	DET
dpc-4183	151	2	toll	toll	NOUN
dpc-4183	151	3	-	-	PUNCT
dpc-4183	151	4	like	like	ADJ
dpc-4183	151	5	receptor	receptor	NOUN
dpc-4183	151	6	4	4	NUM
dpc-4183	151	7	ligands	ligand	NOUN
dpc-4183	151	8	mrp8	mrp8	NOUN
dpc-4183	151	9	and	and	CCONJ
dpc-4183	151	10	mrp14	mrp14	PROPN
dpc-4183	151	11	are	be	AUX
dpc-4183	151	12	crucial	crucial	ADJ
dpc-4183	151	13	in	in	ADP
dpc-4183	151	14	the	the	DET
dpc-4183	151	15	development	development	NOUN
dpc-4183	151	16	of	of	ADP
dpc-4183	151	17	autoreactive	autoreactive	PROPN
dpc-4183	151	18	cd8	cd8	PROPN
dpc-4183	151	19	+	+	PROPN
dpc-4183	151	20	t	t	NOUN
dpc-4183	151	21	cells	cell	NOUN
dpc-4183	151	22	.	.	PUNCT
dpc-4183	152	1	nat	nat	PROPN
dpc-4183	152	2	med	med	PROPN
dpc-4183	152	3	.	.	PUNCT
dpc-4183	153	1	2010;16(6):713	2010;16(6):713	NUM
dpc-4183	153	2	-	-	PUNCT
dpc-4183	153	3	7	7	NUM
dpc-4183	153	4	.	.	NUM
dpc-4183	153	5	17	17	NUM
dpc-4183	153	6	.	.	PUNCT
dpc-4183	154	1	petersen	petersen	PROPN
dpc-4183	154	2	b	b	PROPN
dpc-4183	154	3	,	,	PUNCT
dpc-4183	154	4	wolf	wolf	PROPN
dpc-4183	154	5	m	m	PROPN
dpc-4183	154	6	,	,	PUNCT
dpc-4183	154	7	austermann	austermann	PROPN
dpc-4183	154	8	j	j	PROPN
dpc-4183	154	9	,	,	PUNCT
dpc-4183	154	10	van	van	PROPN
dpc-4183	154	11	lent	lend	VERB
dpc-4183	154	12	p	p	NOUN
dpc-4183	154	13	,	,	PUNCT
dpc-4183	154	14	foell	foell	PROPN
dpc-4183	154	15	d	d	PROPN
dpc-4183	154	16	,	,	PUNCT
dpc-4183	154	17	ahlmann	ahlmann	PROPN
dpc-4183	154	18	m	m	PROPN
dpc-4183	154	19	,	,	PUNCT
dpc-4183	154	20	et	et	PROPN
dpc-4183	154	21	al	al	PROPN
dpc-4183	154	22	.	.	PUNCT
dpc-4183	155	1	the	the	DET
dpc-4183	155	2	alarmin	alarmin	PROPN
dpc-4183	155	3	mrp8/14	mrp8/14	PROPN
dpc-4183	155	4	as	as	ADP
dpc-4183	155	5	regulator	regulator	NOUN
dpc-4183	155	6	of	of	ADP
dpc-4183	155	7	the	the	DET
dpc-4183	155	8	adaptive	adaptive	ADJ
dpc-4183	155	9	immune	immune	ADJ
dpc-4183	155	10	response	response	NOUN
dpc-4183	155	11	during	during	ADP
dpc-4183	155	12	allergic	allergic	ADJ
dpc-4183	155	13	contact	contact	NOUN
dpc-4183	155	14	dermatitis	dermatitis	NOUN
dpc-4183	155	15	.	.	PUNCT
dpc-4183	156	1	embo	embo	PROPN
dpc-4183	156	2	j.	j.	PROPN
dpc-4183	156	3	2013;32(1):100	2013;32(1):100	PROPN
dpc-4183	156	4	-	-	PUNCT
dpc-4183	156	5	11	11	NUM
dpc-4183	156	6	.	.	PUNCT
dpc-4183	156	7	18	18	NUM
dpc-4183	156	8	.	.	PUNCT
dpc-4183	157	1	stascheit	stascheit	PROPN
dpc-4183	157	2	f	f	PROPN
dpc-4183	157	3	,	,	PUNCT
dpc-4183	157	4	hotter	hot	ADJ
dpc-4183	157	5	b	b	NOUN
dpc-4183	157	6	,	,	PUNCT
dpc-4183	157	7	hoffmann	hoffmann	PROPN
dpc-4183	157	8	s	s	PROPN
dpc-4183	157	9	,	,	PUNCT
dpc-4183	157	10	et	et	PROPN
dpc-4183	157	11	al	al	PROPN
dpc-4183	157	12	.	.	PROPN
dpc-4183	157	13	calprotectin	calprotectin	NOUN
dpc-4183	157	14	as	as	ADP
dpc-4183	157	15	potential	potential	ADJ
dpc-4183	157	16	novel	novel	NOUN
dpc-4183	157	17	biomarker	biomarker	NOUN
dpc-4183	157	18	in	in	ADP
dpc-4183	157	19	myasthenia	myasthenia	NOUN
dpc-4183	157	20	gravis	gravis	PROPN
dpc-4183	157	21	.	.	PUNCT
dpc-4183	158	1	j	j	PROPN
dpc-4183	158	2	transl	transl	PROPN
dpc-4183	158	3	autoimmun	autoimmun	PROPN
dpc-4183	158	4	.	.	PUNCT
dpc-4183	159	1	2021;4:100111	2021;4:100111	PROPN
dpc-4183	159	2	.	.	PUNCT
dpc-4183	160	1	19	19	NUM
dpc-4183	160	2	.	.	PROPN
dpc-4183	160	3	badran	badran	PROPN
dpc-4183	160	4	ay	ay	INTJ
dpc-4183	160	5	,	,	PUNCT
dpc-4183	160	6	gomaa	gomaa	ADJ
dpc-4183	160	7	as	as	ADP
dpc-4183	160	8	,	,	PUNCT
dpc-4183	160	9	el	el	PROPN
dpc-4183	160	10	-	-	PUNCT
dpc-4183	160	11	mahdy	mahdy	PROPN
dpc-4183	160	12	ri	ri	PROPN
dpc-4183	160	13	,	,	PUNCT
dpc-4183	160	14	el	el	PROPN
dpc-4183	160	15	zohne	zohne	PROPN
dpc-4183	160	16	ra	ra	PROPN
dpc-4183	160	17	,	,	PUNCT
dpc-4183	160	18	kamal	kamal	PROPN
dpc-4183	160	19	dt	dt	PROPN
dpc-4183	160	20	,	,	PUNCT
dpc-4183	160	21	abou	abou	ADJ
dpc-4183	160	22	-	-	PUNCT
dpc-4183	160	23	taleb	taleb	NOUN
dpc-4183	160	24	dae	dae	NOUN
dpc-4183	160	25	.	.	PUNCT
dpc-4183	160	26	serum	serum	NOUN
dpc-4183	160	27	level	level	NOUN
dpc-4183	160	28	of	of	ADP
dpc-4183	160	29	s100b	s100b	PROPN
dpc-4183	160	30	in	in	ADP
dpc-4183	160	31	vitiligo	vitiligo	NOUN
dpc-4183	160	32	patients	patient	NOUN
dpc-4183	160	33	:	:	PUNCT
dpc-4183	160	34	is	be	AUX
dpc-4183	160	35	it	it	PRON
dpc-4183	160	36	a	a	DET
dpc-4183	160	37	marker	marker	NOUN
dpc-4183	160	38	of	of	ADP
dpc-4183	160	39	disease	disease	NOUN
dpc-4183	160	40	activity	activity	NOUN
dpc-4183	160	41	?	?	PUNCT
dpc-4183	161	1	australas	australas	PROPN
dpc-4183	161	2	j	j	PROPN
dpc-4183	161	3	dermatol	dermatol	NOUN
dpc-4183	161	4	.	.	PUNCT
dpc-4183	162	1	2021;62(1	2021;62(1	NUM
dpc-4183	162	2	):	):	PUNCT
dpc-4183	162	3	e67	e67	NOUN
dpc-4183	162	4	-	-	PUNCT
dpc-4183	162	5	e72	e72	PROPN
dpc-4183	162	6	.	.	PUNCT
dpc-4183	163	1	20	20	NUM
dpc-4183	163	2	.	.	PUNCT
dpc-4183	164	1	kubelis	kubelis	PROPN
dpc-4183	164	2	-	-	PUNCT
dpc-4183	164	3	lópez	lópez	PROPN
dpc-4183	164	4	de	de	X
dpc-4183	164	5	,	,	PUNCT
dpc-4183	164	6	zapata	zapata	NOUN
dpc-4183	164	7	-	-	PUNCT
dpc-4183	164	8	salazar	salazar	PROPN
dpc-4183	164	9	na	na	NOUN
dpc-4183	164	10	,	,	PUNCT
dpc-4183	164	11	said	say	VERB
dpc-4183	164	12	-	-	PUNCT
dpc-4183	164	13	fernández	fernández	PROPN
dpc-4183	164	14	sl	sl	INTJ
dpc-4183	164	15	,	,	PUNCT
dpc-4183	164	16	et	et	PROPN
dpc-4183	164	17	al	al	PROPN
dpc-4183	164	18	.	.	PROPN
dpc-4183	165	1	updates	update	NOUN
dpc-4183	165	2	and	and	CCONJ
dpc-4183	165	3	new	new	ADJ
dpc-4183	165	4	medical	medical	ADJ
dpc-4183	165	5	treatments	treatment	NOUN
dpc-4183	165	6	for	for	ADP
dpc-4183	165	7	vitiligo	vitiligo	NOUN
dpc-4183	165	8	(	(	PUNCT
dpc-4183	165	9	review	review	NOUN
dpc-4183	165	10	)	)	PUNCT
dpc-4183	165	11	.	.	PUNCT
dpc-4183	166	1	exp	exp	NOUN
dpc-4183	166	2	ther	ther	PROPN
dpc-4183	166	3	med	med	PROPN
dpc-4183	166	4	.	.	PUNCT
dpc-4183	167	1	2021;22(2):797	2021;22(2):797	NUM
dpc-4183	167	2	.	.	PUNCT
dpc-4183	168	1	6	6	NUM
dpc-4183	168	2	.	.	PUNCT
dpc-4183	169	1	liu	liu	PROPN
dpc-4183	169	2	b	b	PROPN
dpc-4183	169	3	,	,	PUNCT
dpc-4183	169	4	xie	xie	PROPN
dpc-4183	169	5	y	y	PROPN
dpc-4183	169	6	,	,	PUNCT
dpc-4183	169	7	wu	wu	PROPN
dpc-4183	169	8	z.	z.	PROPN
dpc-4183	169	9	identification	identification	NOUN
dpc-4183	169	10	of	of	ADP
dpc-4183	169	11	candidate	candidate	NOUN
dpc-4183	169	12	genes	gene	NOUN
dpc-4183	169	13	and	and	CCONJ
dpc-4183	169	14	pathways	pathway	NOUN
dpc-4183	169	15	in	in	ADP
dpc-4183	169	16	nonsegmental	nonsegmental	NOUN
dpc-4183	169	17	vitiligo	vitiligo	NOUN
dpc-4183	169	18	using	use	VERB
dpc-4183	169	19	integrated	integrate	VERB
dpc-4183	169	20	bioinformatics	bioinformatics	NOUN
dpc-4183	169	21	methods	method	NOUN
dpc-4183	169	22	.	.	PUNCT
dpc-4183	170	1	dermatology	dermatology	NOUN
dpc-4183	170	2	.	.	PUNCT
dpc-4183	171	1	2021;237(3):464	2021;237(3):464	NUM
dpc-4183	171	2	-	-	SYM
dpc-4183	171	3	72	72	NUM
dpc-4183	171	4	.	.	PUNCT
dpc-4183	171	5	7	7	X
dpc-4183	171	6	.	.	X
dpc-4183	171	7	stríz	stríz	VERB
dpc-4183	171	8	i	i	PRON
dpc-4183	171	9	,	,	PUNCT
dpc-4183	172	1	trebichavský	trebichavský	PROPN
dpc-4183	172	2	i.	i.	PROPN
dpc-4183	172	3	calprotectin	calprotectin	PROPN
dpc-4183	172	4	a	a	DET
dpc-4183	172	5	pleiotropic	pleiotropic	ADJ
dpc-4183	172	6	molecule	molecule	NOUN
dpc-4183	172	7	in	in	ADP
dpc-4183	172	8	acute	acute	ADJ
dpc-4183	172	9	and	and	CCONJ
dpc-4183	172	10	chronic	chronic	ADJ
dpc-4183	172	11	inflammation	inflammation	NOUN
dpc-4183	172	12	.	.	PUNCT
dpc-4183	173	1	physiol	physiol	PROPN
dpc-4183	173	2	res	re	NOUN
dpc-4183	173	3	.	.	PUNCT
dpc-4183	174	1	2004;53(3):245	2004;53(3):245	NUM
dpc-4183	174	2	-	-	SYM
dpc-4183	174	3	53	53	NUM
dpc-4183	174	4	.	.	NOUN
dpc-4183	174	5	8	8	NUM
dpc-4183	174	6	.	.	PUNCT
dpc-4183	175	1	jukic	jukic	PROPN
dpc-4183	175	2	a	a	DET
dpc-4183	175	3	,	,	PUNCT
dpc-4183	175	4	bakiri	bakiri	NOUN
dpc-4183	175	5	l	l	PROPN
dpc-4183	175	6	,	,	PUNCT
dpc-4183	175	7	wagner	wagner	PROPN
dpc-4183	175	8	ef	ef	PROPN
dpc-4183	175	9	,	,	PUNCT
dpc-4183	175	10	tilg	tilg	NOUN
dpc-4183	175	11	h	h	NOUN
dpc-4183	175	12	,	,	PUNCT
dpc-4183	175	13	adolph	adolph	PROPN
dpc-4183	175	14	te	te	PROPN
dpc-4183	175	15	.	.	PUNCT
dpc-4183	176	1	calprotectin	calprotectin	PROPN
dpc-4183	176	2	:	:	PUNCT
dpc-4183	176	3	from	from	ADP
dpc-4183	176	4	biomarker	biomarker	NOUN
dpc-4183	176	5	to	to	ADP
dpc-4183	176	6	biological	biological	ADJ
dpc-4183	176	7	function	function	NOUN
dpc-4183	176	8	.	.	PUNCT
dpc-4183	177	1	gut	gut	VERB
dpc-4183	177	2	.	.	PUNCT
dpc-4183	178	1	2021;70(10):1978	2021;70(10):1978	NUM
dpc-4183	178	2	-	-	SYM
dpc-4183	178	3	88	88	NUM
dpc-4183	178	4	.	.	PUNCT
dpc-4183	179	1	9	9	NUM
dpc-4183	179	2	.	.	X
dpc-4183	179	3	jarlborg	jarlborg	PROPN
dpc-4183	179	4	m	m	PROPN
dpc-4183	179	5	,	,	PUNCT
dpc-4183	179	6	courvoisier	courvoisier	NOUN
dpc-4183	179	7	ds	ds	NOUN
dpc-4183	179	8	,	,	PUNCT
dpc-4183	179	9	lamacchia	lamacchia	VERB
dpc-4183	179	10	c	c	PROPN
dpc-4183	179	11	,	,	PUNCT
dpc-4183	179	12	et	et	PROPN
dpc-4183	179	13	al	al	PROPN
dpc-4183	179	14	.	.	PROPN
dpc-4183	180	1	serum	serum	PROPN
dpc-4183	180	2	calprotectin	calprotectin	PROPN
dpc-4183	180	3	:	:	PUNCT
dpc-4183	180	4	a	a	DET
dpc-4183	180	5	promising	promising	ADJ
dpc-4183	180	6	biomarker	biomarker	NOUN
dpc-4183	180	7	in	in	ADP
dpc-4183	180	8	rheumatoid	rheumatoid	NOUN
dpc-4183	180	9	arthritis	arthritis	NOUN
dpc-4183	180	10	and	and	CCONJ
dpc-4183	180	11	axial	axial	ADJ
dpc-4183	180	12	spondyloarthritis	spondyloarthritis	NOUN
dpc-4183	180	13	.	.	PUNCT
dpc-4183	181	1	arthritis	arthritis	NOUN
dpc-4183	181	2	res	re	NOUN
dpc-4183	181	3	ther	ther	ADV
dpc-4183	181	4	.	.	PUNCT
dpc-4183	182	1	2020;22(1):105	2020;22(1):105	NUM
dpc-4183	182	2	.	.	PUNCT
dpc-4183	183	1	10	10	NUM
dpc-4183	183	2	.	.	PUNCT
dpc-4183	184	1	he	he	PRON
dpc-4183	184	2	k	k	PROPN
dpc-4183	184	3	,	,	PUNCT
dpc-4183	184	4	wu	wu	PROPN
dpc-4183	184	5	w	w	PROPN
dpc-4183	184	6	,	,	PUNCT
dpc-4183	184	7	wang	wang	PROPN
dpc-4183	184	8	x	x	PROPN
dpc-4183	184	9	,	,	PUNCT
dpc-4183	184	10	et	et	PROPN
dpc-4183	184	11	al	al	PROPN
dpc-4183	184	12	.	.	PUNCT
dpc-4183	184	13	circulatory	circulatory	ADJ
dpc-4183	184	14	levels	level	NOUN
dpc-4183	184	15	of	of	ADP
dpc-4183	184	16	alarmins	alarmin	NOUN
dpc-4183	184	17	in	in	ADP
dpc-4183	184	18	patients	patient	NOUN
dpc-4183	184	19	with	with	ADP
dpc-4183	184	20	non	non	ADJ
dpc-4183	184	21	-	-	ADJ
dpc-4183	184	22	segmental	segmental	ADJ
dpc-4183	184	23	vitiligo	vitiligo	NOUN
dpc-4183	184	24	:	:	PUNCT
dpc-4183	184	25	potential	potential	ADJ
dpc-4183	184	26	biomarkers	biomarker	NOUN
dpc-4183	184	27	for	for	ADP
dpc-4183	184	28	disease	disease	NOUN
dpc-4183	184	29	diagnosis	diagnosis	NOUN
dpc-4183	184	30	and	and	CCONJ
dpc-4183	184	31	activity	activity	NOUN
dpc-4183	184	32	/	/	SYM
dpc-4183	184	33	severity	severity	NOUN
dpc-4183	184	34	assessment	assessment	NOUN
dpc-4183	184	35	.	.	PUNCT
dpc-4183	185	1	front	front	ADJ
dpc-4183	185	2	immunol	immunol	NOUN
dpc-4183	185	3	.	.	PUNCT
dpc-4183	186	1	2022;13:1069196	2022;13:1069196	NUM
dpc-4183	186	2	.	.	NOUN
dpc-4183	186	3	11	11	NUM
dpc-4183	186	4	.	.	PUNCT
dpc-4183	187	1	hamzavi	hamzavi	PROPN
dpc-4183	187	2	i	i	PRON
dpc-4183	187	3	,	,	PUNCT
dpc-4183	187	4	jain	jain	PROPN
dpc-4183	187	5	h	h	PROPN
dpc-4183	187	6	,	,	PUNCT
dpc-4183	187	7	mclean	mclean	PROPN
dpc-4183	187	8	d	d	PROPN
dpc-4183	187	9	,	,	PUNCT
dpc-4183	187	10	shapiro	shapiro	PROPN
dpc-4183	187	11	j	j	PROPN
dpc-4183	187	12	,	,	PUNCT
dpc-4183	187	13	zeng	zeng	PROPN
dpc-4183	187	14	h	h	PROPN
dpc-4183	187	15	,	,	PUNCT
dpc-4183	187	16	lui	lui	PROPN
dpc-4183	187	17	h.	h.	PROPN
dpc-4183	187	18	parametric	parametric	PROPN
dpc-4183	187	19	modeling	modeling	NOUN
dpc-4183	187	20	of	of	ADP
dpc-4183	187	21	narrowband	narrowband	NOUN
dpc-4183	187	22	uv	uv	NOUN
dpc-4183	187	23	-	-	PUNCT
dpc-4183	187	24	b	b	NOUN
dpc-4183	187	25	phototherapy	phototherapy	NOUN
dpc-4183	187	26	for	for	ADP
dpc-4183	187	27	vitiligo	vitiligo	NOUN
dpc-4183	187	28	using	use	VERB
dpc-4183	187	29	a	a	DET
dpc-4183	187	30	novel	novel	ADJ
dpc-4183	187	31	quantitative	quantitative	ADJ
dpc-4183	187	32	tool	tool	NOUN
dpc-4183	187	33	:	:	PUNCT
dpc-4183	187	34	the	the	DET
dpc-4183	187	35	vitiligo	vitiligo	PROPN
dpc-4183	187	36	area	area	NOUN
dpc-4183	187	37	scoring	score	VERB
dpc-4183	187	38	index	index	NOUN
dpc-4183	187	39	.	.	PUNCT
dpc-4183	188	1	arch	arch	ADJ
dpc-4183	188	2	dermatol	dermatol	NOUN
dpc-4183	188	3	.	.	PUNCT
dpc-4183	189	1	2004;140(6):677	2004;140(6):677	NUM
dpc-4183	189	2	-	-	SYM
dpc-4183	189	3	83	83	NUM
dpc-4183	189	4	.	.	PUNCT
dpc-4183	190	1	12	12	NUM
dpc-4183	190	2	.	.	PUNCT
dpc-4183	190	3	njoo	njoo	PROPN
dpc-4183	190	4	md	md	PROPN
dpc-4183	190	5	,	,	PUNCT
dpc-4183	190	6	das	das	PROPN
dpc-4183	190	7	pk	pk	PROPN
dpc-4183	190	8	,	,	PUNCT
dpc-4183	190	9	bos	bos	PROPN
dpc-4183	190	10	jd	jd	PROPN
dpc-4183	190	11	,	,	PUNCT
dpc-4183	190	12	westerhof	westerhof	PROPN
dpc-4183	190	13	w.	w.	PROPN
dpc-4183	190	14	association	association	PROPN
dpc-4183	190	15	of	of	ADP
dpc-4183	190	16	the	the	DET
dpc-4183	190	17	köbner	köbner	PROPN
dpc-4183	190	18	phenomenon	phenomenon	NOUN
dpc-4183	190	19	with	with	ADP
dpc-4183	190	20	disease	disease	NOUN
dpc-4183	190	21	activity	activity	NOUN
dpc-4183	190	22	and	and	CCONJ
dpc-4183	190	23	therapeutic	therapeutic	ADJ
dpc-4183	190	24	responsiveness	responsiveness	NOUN
dpc-4183	190	25	in	in	ADP
dpc-4183	190	26	vitiligo	vitiligo	NOUN
dpc-4183	190	27	vulgaris	vulgaris	NOUN
dpc-4183	190	28	.	.	PUNCT
dpc-4183	191	1	arch	arch	ADJ
dpc-4183	191	2	dermatol	dermatol	NOUN
dpc-4183	191	3	.	.	PUNCT
dpc-4183	192	1	1999;135(4	1999;135(4	NUM
dpc-4183	192	2	):	):	PUNCT
dpc-4183	192	3	407	407	NUM
dpc-4183	192	4	-	-	SYM
dpc-4183	192	5	13	13	NUM
dpc-4183	192	6	.	.	NOUN
dpc-4183	193	1	13	13	NUM
dpc-4183	193	2	.	.	PUNCT
dpc-4183	193	3	alghamdi	alghamdi	PROPN
dpc-4183	193	4	km	km	PROPN
dpc-4183	193	5	,	,	PUNCT
dpc-4183	193	6	kumar	kumar	PROPN
dpc-4183	193	7	a	a	PROPN
dpc-4183	193	8	,	,	PUNCT
dpc-4183	193	9	taïeb	taïeb	NOUN
dpc-4183	193	10	a	a	PRON
dpc-4183	193	11	,	,	PUNCT
dpc-4183	193	12	ezzedine	ezzedine	PROPN
dpc-4183	193	13	k.	k.	PROPN
dpc-4183	193	14	assessment	assessment	NOUN
dpc-4183	193	15	methods	method	NOUN
dpc-4183	193	16	for	for	ADP
dpc-4183	193	17	the	the	DET
dpc-4183	193	18	evaluation	evaluation	NOUN
dpc-4183	193	19	of	of	ADP
dpc-4183	193	20	vitiligo	vitiligo	NOUN
dpc-4183	193	21	.	.	PUNCT
dpc-4183	194	1	j	j	PROPN
dpc-4183	194	2	eur	eur	PROPN
dpc-4183	194	3	acad	acad	PROPN
dpc-4183	194	4	dermatol	dermatol	NOUN
dpc-4183	194	5	venereol	venereol	NOUN
dpc-4183	194	6	.	.	PUNCT
dpc-4183	195	1	2012;26(12):1463	2012;26(12):1463	NUM
dpc-4183	195	2	-	-	SYM
dpc-4183	195	3	71	71	NUM
dpc-4183	195	4	.	.	PUNCT